WO2017131237A1 - 人工単一ガイドrna及びその用途 - Google Patents
人工単一ガイドrna及びその用途 Download PDFInfo
- Publication number
- WO2017131237A1 WO2017131237A1 PCT/JP2017/003251 JP2017003251W WO2017131237A1 WO 2017131237 A1 WO2017131237 A1 WO 2017131237A1 JP 2017003251 W JP2017003251 W JP 2017003251W WO 2017131237 A1 WO2017131237 A1 WO 2017131237A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- represented
- guide rna
- single guide
- sgrna
- Prior art date
Links
- 108020005004 Guide RNA Proteins 0.000 title claims abstract description 72
- 108091033409 CRISPR Proteins 0.000 claims abstract description 99
- 230000000694 effects Effects 0.000 claims abstract description 62
- 239000002773 nucleotide Substances 0.000 claims abstract description 47
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 41
- 125000005647 linker group Chemical group 0.000 claims abstract description 24
- 230000007018 DNA scission Effects 0.000 claims abstract description 9
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 104
- 229910052799 carbon Inorganic materials 0.000 claims description 62
- 108020004414 DNA Proteins 0.000 claims description 61
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 52
- 238000003776 cleavage reaction Methods 0.000 claims description 51
- 230000007017 scission Effects 0.000 claims description 51
- 125000001424 substituent group Chemical group 0.000 claims description 50
- 125000004429 atom Chemical group 0.000 claims description 49
- 229910052760 oxygen Inorganic materials 0.000 claims description 46
- 125000006239 protecting group Chemical group 0.000 claims description 43
- 238000003786 synthesis reaction Methods 0.000 claims description 43
- 239000000126 substance Substances 0.000 claims description 41
- 229910052717 sulfur Inorganic materials 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 37
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 35
- 125000002947 alkylene group Chemical group 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 229940024606 amino acid Drugs 0.000 claims description 30
- 235000001014 amino acid Nutrition 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 239000000178 monomer Substances 0.000 claims description 19
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 229920000570 polyether Polymers 0.000 claims description 18
- 102000053602 DNA Human genes 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 239000001301 oxygen Chemical group 0.000 claims description 13
- 235000018102 proteins Nutrition 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000006245 phosphate protecting group Chemical group 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 239000011593 sulfur Chemical group 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 229960002429 proline Drugs 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- JWYOAMOZLZXDER-UHFFFAOYSA-N 2-azaniumylcyclopentane-1-carboxylate Chemical compound NC1CCCC1C(O)=O JWYOAMOZLZXDER-UHFFFAOYSA-N 0.000 claims description 3
- BOOMHTFCWOJWFO-UHFFFAOYSA-N 3-aminopyridine-2-carboxylic acid Chemical compound NC1=CC=CN=C1C(O)=O BOOMHTFCWOJWFO-UHFFFAOYSA-N 0.000 claims description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 229940000635 beta-alanine Drugs 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 3
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002591 hydroxyproline Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 21
- 238000001727 in vivo Methods 0.000 abstract description 20
- 108091028113 Trans-activating crRNA Proteins 0.000 abstract description 15
- 238000003556 assay Methods 0.000 abstract description 2
- -1 hydroxy, carboxy, sulfo Chemical group 0.000 description 164
- 150000001875 compounds Chemical class 0.000 description 77
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 73
- 239000002904 solvent Substances 0.000 description 51
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 47
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 44
- 239000000203 mixture Substances 0.000 description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- 229920006395 saturated elastomer Polymers 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 25
- 125000000217 alkyl group Chemical group 0.000 description 23
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 23
- 235000017557 sodium bicarbonate Nutrition 0.000 description 23
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 17
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 17
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 108091027544 Subgenomic mRNA Proteins 0.000 description 15
- 238000005520 cutting process Methods 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 239000012043 crude product Substances 0.000 description 14
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 14
- 230000003007 single stranded DNA break Effects 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 108091079001 CRISPR RNA Proteins 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 238000010362 genome editing Methods 0.000 description 12
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 239000013076 target substance Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 101710163270 Nuclease Proteins 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 9
- YQVISGXICTVSDQ-UHFFFAOYSA-O [c-]1nn[nH]n1.CC(C)[NH2+]C(C)C Chemical compound [c-]1nn[nH]n1.CC(C)[NH2+]C(C)C YQVISGXICTVSDQ-UHFFFAOYSA-O 0.000 description 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 9
- 125000004103 aminoalkyl group Chemical group 0.000 description 9
- 239000012300 argon atmosphere Substances 0.000 description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 9
- 125000002541 furyl group Chemical group 0.000 description 9
- 150000002430 hydrocarbons Chemical group 0.000 description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 125000001188 haloalkyl group Chemical group 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
- 101150105104 Kras gene Proteins 0.000 description 7
- 101150057615 Syn gene Proteins 0.000 description 7
- 125000002877 alkyl aryl group Chemical group 0.000 description 7
- 108700041737 bcl-2 Genes Proteins 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 6
- JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 101150048834 braF gene Proteins 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229910052754 neon Inorganic materials 0.000 description 6
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 150000003222 pyridines Chemical class 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 239000007984 Tris EDTA buffer Substances 0.000 description 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
- 229960005542 ethidium bromide Drugs 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 5
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- 230000006780 non-homologous end joining Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 3
- QMQXVNHINOVNSD-UHFFFAOYSA-N 2-[chloro(diphenyl)methyl]-5,5-dimethoxycyclohexa-1,3-diene Chemical compound C1=CC(OC)(OC)CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 QMQXVNHINOVNSD-UHFFFAOYSA-N 0.000 description 3
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 3
- RKVHNYJPIXOHRW-UHFFFAOYSA-N 3-bis[di(propan-2-yl)amino]phosphanyloxypropanenitrile Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N RKVHNYJPIXOHRW-UHFFFAOYSA-N 0.000 description 3
- DFMCZPLZFNEJLW-UHFFFAOYSA-N 3-bis[di(propan-2-yl)amino]phosphanylperoxypropanenitrile Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OOCCC#N DFMCZPLZFNEJLW-UHFFFAOYSA-N 0.000 description 3
- IWHLYPDWHHPVAA-UHFFFAOYSA-N 6-hydroxyhexanoic acid Chemical compound OCCCCCC(O)=O IWHLYPDWHHPVAA-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 101100381516 Homo sapiens BCL2 gene Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- YJCJVMMDTBEITC-UHFFFAOYSA-N 10-hydroxycapric acid Chemical compound OCCCCCCCCCC(O)=O YJCJVMMDTBEITC-UHFFFAOYSA-N 0.000 description 2
- ZDHCZVWCTKTBRY-UHFFFAOYSA-N 12-hydroxylauric acid Chemical compound OCCCCCCCCCCCC(O)=O ZDHCZVWCTKTBRY-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 2
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- KDMSVYIHKLZKET-UHFFFAOYSA-N 8-hydroxyoctanoic acid Chemical compound OCCCCCCCC(O)=O KDMSVYIHKLZKET-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 101000860092 Francisella tularensis subsp. novicida (strain U112) CRISPR-associated endonuclease Cas12a Proteins 0.000 description 2
- 108010008488 Glycylglycine Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101100381977 Homo sapiens BRAF gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 241001112693 Lachnospiraceae Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000005336 allyloxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 229940043257 glycylglycine Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- QTNLALDFXILRQO-UHFFFAOYSA-N nonadecane-1,2,3-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)CO QTNLALDFXILRQO-UHFFFAOYSA-N 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 230000009438 off-target cleavage Effects 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000008298 phosphoramidates Chemical group 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical group C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Chemical group C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- WLWNRAWQDZRXMB-YLFCFFPRSA-N (2r,3r,4r,5s)-n,3,4,5-tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 WLWNRAWQDZRXMB-YLFCFFPRSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- AQTUACKQXJNHFQ-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(O)=O AQTUACKQXJNHFQ-LURJTMIESA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 description 1
- ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 1,2-dihydrophenazine Chemical compound C1=CC=C2N=C(C=CCC3)C3=NC2=C1 ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Chemical group OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- MZMNEDXVUJLQAF-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)C1CC(O)CN1C(=O)OC(C)(C)C MZMNEDXVUJLQAF-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- SWVSKCPPMNGBGL-UHFFFAOYSA-N 10-aminodecan-1-ol Chemical compound NCCCCCCCCCCO SWVSKCPPMNGBGL-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- AZUHIVLOSAPWDM-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)-1h-imidazole Chemical compound C1=CNC(C=2NC=CN=2)=N1 AZUHIVLOSAPWDM-UHFFFAOYSA-N 0.000 description 1
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VPLZGVOSFFCKFC-UHFFFAOYSA-N 3-methyluracil Chemical compound CN1C(=O)C=CNC1=O VPLZGVOSFFCKFC-UHFFFAOYSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical class [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- WPQLFQWYPPALOX-UHFFFAOYSA-N 5-(2-aminopropyl)-1h-pyrimidine-2,4-dione Chemical compound CC(N)CC1=CNC(=O)NC1=O WPQLFQWYPPALOX-UHFFFAOYSA-N 0.000 description 1
- HFTVVHMKHFDYBV-UHFFFAOYSA-N 5-(methylaminomethyl)-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CNCC1=CNC(=S)NC1=O HFTVVHMKHFDYBV-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical class [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- WDCOJSGXSPGNFK-UHFFFAOYSA-N 8-aminooctan-1-ol Chemical compound NCCCCCCCCO WDCOJSGXSPGNFK-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 241000093740 Acidaminococcus sp. Species 0.000 description 1
- 101000860090 Acidaminococcus sp. (strain BV3L6) CRISPR-associated endonuclease Cas12a Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PIJBIKNGJOHGFP-UHFFFAOYSA-N CN1C(N=CC=C1N)=O.NC(CCN1C(NC=CC1=O)=O)C(=O)O Chemical compound CN1C(N=CC=C1N)=O.NC(CCN1C(NC=CC1=O)=O)C(=O)O PIJBIKNGJOHGFP-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Chemical group CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101100086477 Homo sapiens KRAS gene Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- IJCKBIINTQEGLY-UHFFFAOYSA-N N(4)-acetylcytosine Chemical compound CC(=O)NC1=CC=NC(=O)N1 IJCKBIINTQEGLY-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- NGGZRRDMJNCKFM-UHFFFAOYSA-N NCCCCO.O.ON1N=NC2=C1C=CC=C2 Chemical compound NCCCCO.O.ON1N=NC2=C1C=CC=C2 NGGZRRDMJNCKFM-UHFFFAOYSA-N 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- BUTXDQDSXGXGHI-UHFFFAOYSA-N OP(O)=O.NP(O)(O)=O Chemical compound OP(O)=O.NP(O)(O)=O BUTXDQDSXGXGHI-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical group OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000007960 acetonitrile Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 125000002078 anthracen-1-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C([*])=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 125000000748 anthracen-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C([H])=C([*])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WNTGVOIBBXFMLR-UHFFFAOYSA-N bicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1C2 WNTGVOIBBXFMLR-UHFFFAOYSA-N 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Chemical group C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Chemical group C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical group 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- DJLUSNAYRNFVSM-UHFFFAOYSA-N methyl 2-(2,4-dioxo-1h-pyrimidin-5-yl)acetate Chemical compound COC(=O)CC1=CNC(=O)NC1=O DJLUSNAYRNFVSM-UHFFFAOYSA-N 0.000 description 1
- DGRUIWRQODIJRI-UHFFFAOYSA-N methyl 2-(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)acetate Chemical compound COC(=O)CC1=CNC(=S)NC1=O DGRUIWRQODIJRI-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- FZQMZXGTZAPBAK-UHFFFAOYSA-N n-(3-methylbutyl)-7h-purin-6-amine Chemical compound CC(C)CCNC1=NC=NC2=C1NC=N2 FZQMZXGTZAPBAK-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Chemical group 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical compound OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- MHSKRLJMQQNJNC-UHFFFAOYSA-N terephthalamide Chemical compound NC(=O)C1=CC=C(C(N)=O)C=C1 MHSKRLJMQQNJNC-UHFFFAOYSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to an artificial single guide RNA (hereinafter also referred to as “sgRNA”) having an activity equal to or higher than that of a natural type and improved in vivo stability, the artificial sgRNA and CRISPR-associated protein 9 (Cas9 ) In combination with CRISPR / Cas9 system and its use.
- sgRNA artificial single guide RNA
- Cas9 CRISPR-associated protein 9
- CRISPR clustered, regularly interspaced, short, palindromic repeats
- CRISPR is a short sequence of several tens of base pairs present in bacteria, and is involved in the acquired immune mechanism against foreign DNA such as bacteriophages and plasmids.
- PAM proto-spacer adjacent motif
- the inserted target sequence is transcribed as a series of CRISPR RNA (crRNA) precursors together with the repetitive sequence, and then the repetitive sequence is cleaved by the action of trans-activating crRNA (tracrRNA) partially complementary to crRNA to become mature crRNA.
- the complex forms a complex with Cas9, a double-strand break endonuclease in one of the tracrRNA and Cas gene groups.
- the complex recognizes the PAM sequence in the foreign DNA and binds to a target sequence adjacent thereto, and Cas9 cuts and removes the foreign DNA. This series of mechanisms is called the CRISPR / Cas9 system.
- N is each independently A, G, C, or U, and (n) 20 represents a guide region of crRNA.
- TracrRNA is required for maturation of crRNA and complex formation with Cas9 via the hairpin structure formed with crRNA, but the 3 'end of crRNA and the 5' end of tracrRNA are shortened via a nucleotide linker.
- sgRNA single guide RNA
- Cas9 derived from Streptococcus pyogenes (SpCas9) recognizes NGG as PAM, so if GG is present on the 3 'side, you can replace any 20 bases on the 5' end side of the sgRNA with the desired target sequence.
- Double-stranded DNA break can be cleaved at the target site.
- sgRNA is introduced into cells together with Cas9 mRNA or protein, or DNA encoding Cas9, in the form of natural RNA generated using an in vitro transcription system or recombinant cells, or in the form of DNA encoding sgRNA.
- the sgRNA introduced into (expressed in) the cell and the Cas9 protein form a complex, which binds to the target sequence and generates a DSB in the target gene.
- the DSB is repaired by non-homologous end joining (NHEJ), but the target gene is destroyed by a frameshift mutation caused by accidental base insertion / deletion (indel).
- NHEJ non-homologous end joining
- indel accidental base insertion / deletion
- DSB is accompanied by unexpected genome modification by off-target cleavage, so there are side effects such as strong cytotoxicity and chromosomal translocation, and there are very few surviving cells, or genetic modification itself is difficult for single-cell microorganisms.
- DNA expression vectors encoding sgRNA and Cas9 is associated with persistent expression of sgRNA and Cas9, so there is a greater problem of off-target cleavage and there is also a risk of gene disruption due to the integration of the expression vector into the chromosome .
- RNA By introducing sgRNA in the form of RNA and Cas9 in the form of mRNA or protein, the above problems can be avoided or reduced, but natural (unmodified) RNA is unstable in vivo. There is a problem of reduced genome editing efficiency in vivo.
- Non-patent Document 1 shows that the chemically modified sgRNA in which the 2 'position of the ribose at the 5' and 3 'terminal nucleotides and the phosphodiester bond are modified significantly improved genome editing efficiency in human primary cultured cells.
- Non-patent Document 1 shows that the chemically modified sgRNA in which the 2 'position of the ribose at the 5' and 3 'terminal nucleotides and the phosphodiester bond are modified significantly improved genome editing efficiency in human primary cultured cells.
- RNA is unstable in vivo, and it can also be used for recombination and in In production by in vitro transcription, preparation of vectors and template DNA is necessary, and there are problems that time and labor are required for culture, enzyme reaction, and RNA purification.
- chemically modified RNA it cannot be said that the genome editing efficiency, particularly the efficiency of introducing gene insertion mutation by homologous recombination, is sufficient.
- an object of the present invention is to provide a novel artificial sgRNA having an activity equal to or higher than that of natural RNA and having improved in vivo stability, and by combining the artificial sgRNA and Cas9. It is to provide a more efficient CRISPR / Cas9 system.
- the present inventors have prepared a nucleotide linker for linking sgRNA between the 3 ′ end of crRNA and the 5 ′ end of tracrRNA (in the sgRNA corresponding to SpCas9 (the following formula), 5′-GAAA- Even if the 3 'tetraloop (see Nishimasu et al., Cell, 156: 935-949 (2014)) part is replaced with an amino acid derivative linker, the in vitro (cell-free or intracellular) In the DNA cleavage assay, it was found that the activity was equal to or better than the original sgRNA.
- linker region existing between stem-loop 1 and stem-loop 2 of tracrRNA and / or the loop portion of stem-loop 2 is replaced with an amino acid derivative linker, or the 5 ′ end and / or 3 ′ end of sgRNA It has also been found that even when an amino acid derivative linker is added / inserted in the vicinity (lower arrow), at least the activity equal to or higher than that of the original sgRNA is retained in a cell-free system.
- N is each independently A, G, C, or U, and (n) 20 represents a guide region of crRNA.
- the present inventors introduced sgRNA with one or more amino acid derivative linkers to maintain the sgRNA activity (target double-stranded DNA cleavage activity in combination with Cas9) while maintaining the sgRNA in vivo.
- the present invention has been completed by succeeding in improving the stability.
- X 1 and X 2 are each independently H 2 , O, S or NH; Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S; L 1 is an alkylene chain having n carbon atoms, and a hydrogen atom on the alkylene carbon atom is substituted with OH, OR a , NH 2 , NHR a , NR a R b , SH, or SR a May not be substituted, or L 1 is a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom, However, when Y 1 is NH, O or S, the atom of L 1 bonded to Y 1 is carbon, the atom of L 1 bonded to OR 1 is carbon, and oxygen atoms are not adjacent to each other; L 2 is an alkylene chain having m carbon atoms, and a hydrogen atom on the alkylene carbon atom may be substituted with OH,
- L 2 is a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom
- R a , R b , R c and R d are each independently a substituent or a protecting group
- m is an integer from 0 to 30
- n is an integer from 0 to 30
- R 1 and R 2 may or may not be present, and when present, R 1 and R 2 are each independently a nucleotide residue or structure (I) above
- A is any atomic group, provided that the following formula (Ia) is an amino acid or a peptide.
- An amino acid derivative linker represented by:
- the X a binds to an adjacent nucleotide residue via the —OR 1 — or —OR 2 —;
- X b and Y are each independently any 1 to 5 arbitrary nucleotide linkers, or an amino acid derivative linker represented by the above formula (I), Each of X b and Y independently binds to an adjacent nucleotide residue via the —OR 1 — or —OR 2 —;
- X c and X d may or may not be present, and when present, each independently represents an amino acid derivative linker represented by the above formula (I);
- the X c and X d each independently bind to an adjacent nucleotide residue via the —OR 1 — or —OR 2 —;
- (n) 20 is a nucleotide sequence consisting of 20 ⁇ 5 nucleotide residues each independently A, G, C or U.
- R 100 is an optional substituent, which may or may not be present. When present, one or a plurality of substituents may be present.
- the X a is the formula (I-1) ⁇ (I -7):
- n and m are each independently an integer of 0 to 30.
- X a is represented by the following formula (II):
- X 1 and X 2 are each independently H 2 , O, S or NH; Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S; R 3 is a hydrogen atom or substituent bonded to C-3, C-4, C-5 or C-6 on ring A; L 1 is an alkylene chain of n atoms, substituted where hydrogen atoms on the alkylene carbon atoms are, OH, OR a, NH 2 , NHR a, with NR a R b, SH, or SR a May or may not be substituted, or L 1 is a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom, However, when Y 1 is NH, O or S, the atom of L 1 bonded to Y 1 is carbon, the atom of L 1 bonded to OR 1 is carbon, and oxygen atoms are not adjacent to each other; L 2 is an alkylene chain
- RNA (In each formula, n and m are each independently an integer of 0 to 30, and q is an integer of 0 to 10.) RNA.
- X a is represented by the following formulas (III-1) to (III-3):
- n and m are each independently an integer of 0 to 30.
- a CRISPR / Cas9 system comprising a combination of the single guide RNA according to any one of [1] to [30] and Cas9.
- the artificial sgRNA of the present invention can be easily synthesized at low cost, and can improve the in vivo stability of the sgRNA without impairing the cleavage activity of the target double-stranded DNA. In particular, it can improve genome editing efficiency in vivo.
- the present invention relates to a StrRNA and tracrRNA derived from Streptococcus pyogenes represented by the following formula:
- N is each independently A, G, C, or U
- (n) 20 represents a guide region of crRNA.
- single guide RNA natural sgRNA
- chimerized shortened and single stranded
- a chemically modified sgRNA also referred to herein as “the artificial sgRNA of the present invention” containing at least one or more amino acid derivative linkers in its internal sequence.
- Natural sgRNA that is the origin of the artificial sgRNA of the present invention (originally sgRNA itself is an artificial RNA, but in this specification, natural sgRNA means only sgRNA consisting of “natural (ie, unmodified) nucleotide”)
- the 5 ′ end includes a guide region complementary to the target nucleotide sequence ((n) 20 ), and a downstream from the repeat region derived from crRNA, the anti-repeat region derived from tracrRNA, and Are linked via a tetraloop consisting of 4 nucleotides (GAAA) to form a stem-loop structure.
- GAA tetraloop consisting of 4 nucleotides
- downstream of the anti-repeat region it contains three stem-loop structures derived from tracrRNA, and has a linker region consisting of 5 nucleotides (UUAUC) between stem-loop 1 and stem-loop 2.
- the length of the nucleotide sequence of the guide region ((n) 20 ) need only be sufficient for the sgRNA to specifically bind to the target nucleotide sequence.
- mutation at a specific site in mammalian genomic DNA When introduced, it is 12 nucleotides or more, preferably 15 nucleotides or more, more preferably 17 nucleotides or more, depending on the genome size.
- the upper limit of the length is not particularly limited, but is preferably 25 nucleotides or less, more preferably 22 nucleotides or less. More specifically, the nucleotide length of the guide region is 20 ⁇ 5 nucleotides, preferably 17-22 nucleotides, particularly preferably 20 nucleotides.
- the artificial sgRNA of the present invention is characterized in that the tetraloop portion of the natural sgRNA is substituted with at least an amino acid derivative linker (X a ). That is, the artificial sgRNA of the present invention has the following formula (A):
- X 1 and X 2 are each independently H 2 , O, S or NH; Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S; L 1 is an alkylene chain having n carbon atoms, and a hydrogen atom on the alkylene carbon atom is substituted with OH, OR a , NH 2 , NHR a , NR a R b , SH, or SR a May not be substituted, or L 1 is a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom, However, when Y 1 is NH, O or S, the atom of L 1 bonded to Y 1 is carbon, the atom of L 1 bonded to OR 1 is carbon, and oxygen atoms are not adjacent to each other; L 2 is an alkylene chain having m carbon atoms, and a hydrogen atom on the alkylene carbon atom may be substituted with OH,
- L 2 is a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom
- R a , R b , R c and R d are each independently a substituent or a protecting group
- m is an integer from 0 to 30
- n is an integer from 0 to 30
- R 1 and R 2 may or may not be present, and when present, R 1 and R 2 are each independently a nucleotide residue or structure (I) above
- A is any atomic group, provided that the following formula (Ia) is an amino acid or a peptide.
- An amino acid derivative linker represented by:
- the X a binds to an adjacent nucleotide residue via the —OR 1 — or —OR 2 —;
- X b and Y are each independently any 1 to 5 arbitrary nucleotide linkers, or an amino acid derivative linker represented by the above formula (I), Each of X b and Y independently binds to an adjacent nucleotide residue via the —OR 1 — or —OR 2 —;
- X c and X d may or may not be present, and when present, each independently represents an amino acid derivative linker represented by the above formula (I);
- the X c and X d each independently bind to an adjacent nucleotide residue via the —OR 1 — or —OR 2 —;
- (n) 20 is a nucleotide sequence consisting of 20 ⁇ 5 nucleotide residues each independently A, G, C or U.
- X 1 and X 2 are each independently, for example, H 2 , O, S or NH.
- X 1 being H 2 means that X 1 together with the carbon atom to which X 1 is bonded forms CH 2 (methylene group). The same is true for X 2.
- Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S.
- L 1 is an alkylene chain having n carbon atoms.
- the hydrogen atom on the alkylene carbon atom may be substituted with, for example, OH, OR a , NH 2 , NHR a , NR a R b , SH, or SR a , or may not be substituted.
- L 1 may be a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom.
- the polyether chain is, for example, polyethylene glycol.
- L 2 is an alkylene chain having m carbon atoms.
- the hydrogen atom on the alkylene carbon atom may be substituted with, for example, OH, OR c , NH 2 , NHR c , NR c R d , SH or SR c , or may not be substituted.
- L 2 may be a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom.
- Y 2 is NH, O or S
- the L 2 atom bonded to Y 2 is carbon
- the L 2 atom bonded to OR 2 is carbon
- oxygen atoms are not adjacent to each other. That is, for example, when Y 2 is O, the oxygen atom and the oxygen atom of L 2 are not adjacent, and the oxygen atom of OR 2 and the oxygen atom of L 2 are not adjacent.
- N in L 1 and m in L 2 are not particularly limited, and the lower limit is, for example, 0, and the upper limit is not particularly limited.
- n and m can be appropriately set depending on, for example, the desired length of the linker region (Lx).
- n and m are each preferably 0 to 30, more preferably 0 to 20, and still more preferably 0 to 15 from the viewpoint of production cost and yield.
- n + m is, for example, 0 to 30, preferably 0 to 20, and more preferably 0 to 15.
- R a , R b , R c and R d are, for example, each independently a substituent or a protecting group, and may be the same or different.
- substituents include hydroxy, carboxy, sulfo, halogen, alkyl halide (haloalkyl, eg, CF 3 , CH 2 CF 3 , CH 2 CCl 3 ), nitro, nitroso, cyano, alkyl (eg, methyl, ethyl).
- alkenyl eg, vinyl
- alkynyl eg, ethynyl
- cycloalkyl eg, cyclopropyl, adamantyl
- cycloalkylalkyl eg, cyclohexylmethyl, adamantylmethyl
- cycloalkenyl eg, : Cyclopropenyl
- cyclylalkyl hydroxyalkyl (eg, hydroxymethyl, hydroxyethyl), alkoxyalkyl (eg, methoxymethyl, ethoxymethyl, ethoxyethyl), aryl (eg, phenyl, naphthyl), arylalkyl
- alkenyl eg, vinyl
- alkynyl eg, ethynyl
- cycloalkyl eg, cyclopropyl, adamantyl
- cycloalkylalkyl e
- substituents may be substituted with one or more further substituents or further protecting groups.
- the further substituent is not particularly limited, and may be a substituent according to the above example, for example.
- the further protecting group is not particularly limited, and may be, for example, a protecting group according to the following examples. The same applies to the following.
- the protecting group is, for example, a functional group that converts a highly reactive functional group into an inert state, and includes known protecting groups.
- the description of the literature J. F. W. McOmie, “Protecting Groups in Organic Chemistry” Prenum Press, London and New York, 1973) can be used as the protecting group.
- the protective group is not particularly limited, and examples thereof include tert-butyldimethylsilyl group (TBDMS), bis (2-acetoxyethyloxy) methyl group (ACE), triisopropylsilyloxymethyl group (TOM), 1- (2 -Cyanoethoxy) ethyl group (CEE), 2-cyanoethoxymethyl group (CEM), tolylsulfonylethoxymethyl group (TEM), dimethoxytrityl group (DMTr) and the like.
- R 3 is OR 4
- the protecting group is not particularly limited, and examples thereof include a TBDMS group, an ACE group, a TOM group, a CEE group, a CEM group, and a TEM group.
- silyl-containing groups of the following formulas (P1) and (P2) are exemplified, and among them, any of DMtr group and the silyl-containing group is preferable.
- hydrogen atoms may be independently substituted with halogens such as Cl, Br, F and I, for example.
- X a is, -OR 1 - or -OR 2 - via, bonded to the adjacent nucleotide residues.
- R 1 and R 2 may or may not exist.
- R 1 and R 2 are each independently a nucleotide residue or the structure of formula (I) above.
- X a is an amino acid derivative residue consisting of the structure of the formula (I), the two or more linked structure.
- the structure of the formula (I) may include 1, 2, 3, or 4, for example.
- the structure of (I) may be directly linked or may be bonded via the nucleotide residue, for example.
- the combination of the bond between the adjacent nucleotide residue and —OR 1 — and —OR 2 — is not particularly limited, and examples thereof include any of the following conditions.
- Condition (1) The 3 ′ end of the adjacent nucleotide residue is bonded to the structure of the formula (I) through —OR 2 — and the 5 ′ end of the adjacent nucleotide residue is bonded through —OR 1 —.
- Condition (2) The 3 ′ end of the adjacent nucleotide residue is bonded to the structure of the formula (I) through —OR 1 — and the 5 ′ end of the adjacent nucleotide residue is bonded through —OR 2 —.
- the atomic group A in the above (I) or (Ia) includes, for example, at least one selected from the group consisting of a chain atomic group, an alicyclic atomic group, and an aromatic atomic group. May not be included.
- the chain atomic group is not particularly limited, and examples thereof include alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, silyl, silyloxyalkyl and the like.
- the alicyclic atomic group is not particularly limited, and examples thereof include cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl and the like.
- the aromatic atomic group is not particularly limited, and examples thereof include aryl, arylalkyl, alkylaryl, condensed ring aryl, condensed ring arylalkyl, and condensed ring alkylaryl.
- each atomic group may or may not further have a substituent or a protecting group. In the case of plural substituents or protecting groups, they may be the same or different.
- substituents examples include the substituents exemplified for the above R a , R b , R c and R d , and more specifically, for example, halogen, hydroxy, alkoxy, amino, carboxy, sulfo, nitro Carbamoyl, sulfamoyl, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, alkylaryl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, silyl, silyloxyalkyl, Examples include pyrrolyl and imidazolyl.
- the protecting group is, for example, the same as the protecting group exemplified for R a , R b , R c and R d .
- amino acid refers to any organic compound containing one or more amino groups and carboxy groups in the molecule.
- Peptide refers to an organic compound having a structure in which two or more amino acids are bound by peptide bonds. The peptide bond may have an acid amide structure or an acid imide structure.
- the amino group explicitly shown in the formula (Ia) may be any amino group.
- the carboxy group specified in the formula (Ia) may be any carboxy group.
- the amino acid may be a natural amino acid or an artificial amino acid.
- “natural amino acid” refers to an amino acid having a naturally occurring structure or an optical isomer thereof.
- the method for producing the natural amino acid is not particularly limited, and for example, it may be extracted from nature or synthesized.
- “artificial amino acid” refers to an amino acid having a structure that does not exist in nature. That is, the artificial amino acid refers to a carboxylic acid derivative containing an amino acid, that is, an amino group (an organic compound containing one or more amino groups and carboxy groups in the molecule) and having a structure that does not exist in nature.
- the artificial amino acid preferably does not include a heterocycle.
- the amino acid may be, for example, an amino acid constituting a protein.
- the amino acids include glycine, ⁇ -alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, hydroxylysine, methionine, phenylalanine, serine, threonine, tyrosine, valine, At least selected from the group consisting of proline, 4-hydroxyproline, tryptophan, ⁇ -alanine, 1-amino-2-carboxycyclopentane, aminobenzoic acid, aminopyridinecarboxylic acid, and an amino acid represented by the following chemical formula (Ia2)
- substituents examples include the substituents exemplified for the above R a , R b , R c and R d , and more specifically, for example, halogen, hydroxy, alkoxy, amino, carboxy, sulfo, nitro Carbamoyl, sulfamoyl, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, alkylaryl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, silyl, silyloxyalkyl, Examples include pyrrolyl and imidazolyl.
- the protecting group is, for example, the same as the protecting group exemplified for R a , R b , R c and R d .
- the amino acid or peptide of the chemical formula (Ia) has an isomer such as an optical isomer, a geometric isomer, or a stereoisomer, any isomer may be used.
- R 100 is an arbitrary substituent and may or may not be present. When present, one or a plurality of R 100 may be present, and in the case of a plurality, R 100 may be the same as or different from each other.
- R 100 examples include the substituents exemplified for R a , R b , R c and R d , and more specifically, for example, halogen, hydroxy, alkoxy, amino, Carboxy, sulfo, nitro, carbamoyl, sulfamoyl, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, alkylaryl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, silyl Silyloxyalkyl, pyrrolyl, imidazolyl and the like.
- the structure of the chemical formula (Ia2) may be, for example, the following chemical formula (Ia3).
- the structure of the chemical formula (Ia) is the chemical formula (Ia2)
- the structure of the atomic group A in the chemical formula (I) is represented by the following chemical formula (A2).
- R 100 in the following chemical formula (A2) is the same as R 100 in the chemical formula (Ia2).
- the structure of the chemical formula (Ia) is the chemical formula (Ia3)
- the structure of the atomic group A in the chemical formula (I) is represented by the following chemical formula (A2a).
- Examples of the structure of the chemical formula (I) include the following chemical formulas (I-1) to (I-7).
- n and m are the chemical formulas Same as (I).
- n and m are not particularly limited and are as described above.
- Their structures are shown in the following chemical formulas (I-1a), (I-1b), (I-4a), (I-6a) and (I-7a). Of these, the formulas (I-1b), (I-6a) and (I-7a) are preferable.
- the linker region (X a ) is represented by the following formula (II).
- X 1 and X 2 are each independently H 2 , O, S or NH; Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S; R 3 is a hydrogen atom or substituent bonded to C-3, C-4, C-5 or C-6 on ring A; L 1 is an alkylene chain of n atoms, substituted where hydrogen atoms on the alkylene carbon atoms are, OH, OR a, NH 2 , NHR a, with NR a R b, SH, or SR a May or may not be substituted, or L 1 is a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom, However, when Y 1 is NH, O or S, the atom of L 1 bonded to Y 1 is carbon, the atom of L 1 bonded to OR 1 is carbon, and oxygen atoms are not adjacent to each other; L 2 is an alkylene chain consist
- the ring A may contain a carbon-carbon double bond or a carbon-nitrogen double bond, R 1 and R 2 may or may not be present, and when present, R 1 and R 2 are each independently a nucleotide residue or structure (II) above; Wherein X a is the -OR 1 - or -OR 2 - bind to nucleotide residues adjacent via.
- X 1 and X 2 are each independently, for example, H 2 , O, S or NH.
- X 1 being H 2 means that X 1 forms CH 2 (methylene group) together with the carbon atom to which X 1 is bonded. The same is true for X 2.
- Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S.
- L 1 is an alkylene chain composed of n atoms.
- the hydrogen atom on the alkylene carbon atom may be substituted with, for example, OH, OR a , NH 2 , NHR a , NR a R b , SH, or SR a , or may not be substituted.
- L 1 may be a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom.
- the polyether chain is, for example, polyethylene glycol.
- L 2 is an alkylene chain composed of m atoms.
- the hydrogen atom on the alkylene carbon atom may be substituted with, for example, OH, OR c , NH 2 , NHR c , NR c R d , SH or SR c , or may not be substituted.
- L 2 may be a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom.
- Y 2 is NH, O or S
- the L 2 atom bonded to Y 2 is carbon
- the L 2 atom bonded to OR 2 is carbon
- oxygen atoms are not adjacent to each other. That is, for example, when Y 2 is O, the oxygen atom and the oxygen atom of L 2 are not adjacent, and the oxygen atom of OR 2 and the oxygen atom of L 2 are not adjacent.
- N in L 1 and m in L 2 are not particularly limited, and the lower limit is, for example, 0, and the upper limit is not particularly limited.
- n and m can be appropriately set according to the desired length of the non-nucleotide structure, for example.
- n and m are each preferably 0 to 30, more preferably 0 to 20, and still more preferably 0 to 15 from the viewpoint of production cost and yield.
- n + m is, for example, 0 to 30, preferably 0 to 20, and more preferably 0 to 15.
- R a , R b , R c and R d are, for example, each independently a substituent or a protecting group.
- the substituent and the protecting group are the same as described above, for example.
- hydrogen atoms may be independently substituted with halogens such as Cl, Br, F and I, for example.
- X a is, -OR 1 - or -OR 2 - via, bonded to the adjacent nucleotide residues.
- R 1 and R 2 may or may not exist.
- R 1 and R 2 are each independently a nucleotide residue or the structure of formula (II).
- X a is an amino acid derivative residue consisting of the structure of the formula (II) is, the two or more linked structure.
- the structure of formula (II) may include, for example, 1, 2, 3 or 4. As described above, when a plurality of the structures are included, the structure (II) may be directly linked or may be bonded via the nucleotide residue.
- the combination of the bond between the adjacent nucleotide residue and —OR 1 — and —OR 2 — is not particularly limited, and examples thereof include any of the following conditions.
- Condition (1) The 3 ′ end of the adjacent nucleotide residue is bonded to the structure of the formula (II) through —OR 2 — and the 5 ′ end of the adjacent nucleotide residue is bonded through —OR 1 —.
- Condition (2) The 3 ′ end of the adjacent nucleotide residue is bonded to the structure of the formula (II) through —OR 1 — and the 5 ′ end of the adjacent nucleotide residue is bonded through —OR 2 —.
- l 1 or 2.
- ring A is a 5-membered ring, for example, the pyrrolidine skeleton.
- the pyrrolidine skeleton include a proline skeleton and a prolinol skeleton, and examples thereof include a bivalent structure.
- ring A is a 6-membered ring, for example, the piperidine skeleton.
- one carbon atom other than C-2 on ring A may be substituted with nitrogen, oxygen or sulfur.
- Ring A may contain a carbon-carbon double bond or a carbon-nitrogen double bond in ring A.
- Ring A may be, for example, either L-type or D-type.
- R 3 is a hydrogen atom or a substituent bonded to C-3, C-4, C-5 or C-6 on the ring A.
- R 3 is the above-described substituent, the substituent R 3 may be one, plural, or absent, and when plural, it may be the same or different.
- the substituent R 3 is, for example, halogen, OH, OR 4 , NH 2 , NHR 4 , NR 4 R 5 , SH, SR 4 or an oxo group ( ⁇ O).
- R 4 and R 5 are, for example, each independently a substituent or a protecting group, and may be the same or different.
- substituents include halogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, heterocyclylalkenyl. , Heterocyclylalkyl, heteroarylalkyl, silyl, silyloxyalkyl and the like. The same applies hereinafter.
- the substituent R 3 may be any of these listed substituents.
- the protecting group is, for example, a functional group that converts a highly reactive functional group into an inert state, and includes known protecting groups.
- the description of the literature J. F. W. McOmie, “Protecting Groups in Organic Chemistry” Prenum Press, London and New York, 1973) can be cited as the protecting group.
- the protective group is not particularly limited, and examples thereof include tert-butyldimethylsilyl group (TBDMS), bis (2-acetoxyethyloxy) methyl group (ACE), triisopropylsilyloxymethyl group (TOM), 1- (2 -Cyanoethoxy) ethyl group (CEE), 2-cyanoethoxymethyl group (CEM), tolylsulfonylethoxymethyl group (TEM), dimethoxytrityl group (DMTr) and the like.
- TBDMS tert-butyldimethylsilyl group
- ACE (2-acetoxyethyloxy) methyl group
- TOM triisopropylsilyloxymethyl group
- CEE 2-Cyanoethoxymethyl group
- CEM 2-cyanoethoxymethyl group
- TEM dimethoxytrityl group
- DMTr dimethoxytrityl group
- R 3 is OR 4
- the protecting group is not particularly
- Examples of the structure of the formula (II) include the following formulas (II-1) to (II-9), in which n and m are the same as those in the formula (II).
- q is an integer of 0 to 10.
- n, m and q are not particularly limited and are as described above.
- alkyl includes, for example, a linear or branched alkyl group.
- the number of carbon atoms of the alkyl is not particularly limited, and is, for example, 1 to 30, preferably 1 to 6 or 1 to 4.
- Examples of the alkyl group include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, Examples thereof include n-octyl, n-nonyl, n-decyl and the like.
- Preferred examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl and the like.
- alkenyl includes, for example, linear or branched alkenyl.
- alkenyl include those having one or more double bonds in the alkyl.
- the number of carbon atoms of the alkenyl is not particularly limited, and is the same as, for example, the alkyl, preferably 2 to 8.
- alkenyl include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 3-methyl-2-butenyl and the like.
- alkynyl includes, for example, linear or branched alkynyl.
- alkynyl include those having one or more triple bonds in the alkyl.
- the number of carbon atoms of the alkynyl is not particularly limited, and is the same as, for example, the alkyl, preferably 2 to 8.
- examples of the alkynyl include ethynyl, propynyl, butynyl and the like.
- the alkynyl may further have one or more double bonds, for example.
- aryl includes, for example, a monocyclic aromatic hydrocarbon group and a polycyclic aromatic hydrocarbon group.
- the monocyclic aromatic hydrocarbon group include phenyl and the like.
- the polycyclic aromatic hydrocarbon group include 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl, 9-anthryl, 1-phenanthryl, 2-phenanthryl, 3-phenanthryl, 4-phenanthryl, 9- And phenanthryl.
- Preferable examples include naphthyl such as phenyl, 1-naphthyl and 2-naphthyl.
- heteroaryl includes, for example, a monocyclic aromatic heterocyclic group and a condensed aromatic heterocyclic group.
- heteroaryl include furyl (eg, 2-furyl, 3-furyl), thienyl (eg, 2-thienyl, 3-thienyl), pyrrolyl (eg, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), Imidazolyl (eg, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), pyrazolyl (eg, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), triazolyl (eg, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-4-yl), tetrazolyl (eg 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl), oxazolyl (eg 2-
- cycloalkyl is, for example, a cyclic saturated hydrocarbon group, and the number of carbons is, for example, 3-15.
- the cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, a bridged cyclic hydrocarbon group, a spiro hydrocarbon group, and the like, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. And a bridged cyclic hydrocarbon group.
- the “bridged cyclic hydrocarbon group” includes, for example, bicyclo [2.1.0] pentyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl and bicyclo [3. 2.1] octyl, tricyclo [2.2.1.0] heptyl, bicyclo [3.3.1] nonane, 1-adamantyl, 2-adamantyl and the like.
- examples of the “spiro hydrocarbon group” include spiro [3.4] octyl and the like.
- cycloalkenyl includes, for example, a cyclic unsaturated aliphatic hydrocarbon group, and has, for example, 3 to 7 carbon atoms.
- examples of the group include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and the like, preferably cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like.
- the cycloalkenyl includes, for example, a bridged cyclic hydrocarbon group and a spiro hydrocarbon group having an unsaturated bond in the ring.
- arylalkyl includes, for example, benzyl, 2-phenethyl, naphthalenylmethyl and the like
- cycloalkylalkyl or “cyclylalkyl” includes, for example, cyclohexylmethyl, adamantylmethyl and the like.
- hydroxyalkyl include hydroxymethyl and 2-hydroxyethyl.
- alkoxy includes, for example, the alkyl-O— group, and examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
- Alkoxyalkyl includes, for example, Examples thereof include methoxymethyl and the like, and “aminoalkyl” includes, for example, 2-aminoethyl and the like.
- heterocyclyl is, for example, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, pyrrolidinone, 1-imidazolinyl, 2-imidazolinyl, 4-imidazolinyl, 1 -Imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, imidazolidinone, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, piperidinone, piperidinyl, 2-piperidinyl 4-piperidinyl, 1-piperazinyl, 2-piperazinyl, piperazinone, 2-morpholinyl, 3-morpholinyl, morpholino, tetrahydropyranyl, tetra
- heterocyclylalkyl includes, for example, piperidinylmethyl, piperazinylmethyl and the like
- heterocyclylalkenyl includes, for example, 2-piperidinylethenyl and the like
- heteroarylalkyl Examples include pyridylmethyl and quinolin-3-ylmethyl.
- sil includes a group represented by the formula R 3 Si—, wherein R can be independently selected from the above alkyl, aryl and cycloalkyl, such as trimethylsilyl group, tert-butyldimethylsilyl
- R can be independently selected from the above alkyl, aryl and cycloalkyl, such as trimethylsilyl group, tert-butyldimethylsilyl
- the “silyloxy” includes, for example, a trimethylsilyloxy group
- the “silyloxyalkyl” includes, for example, trimethylsilyloxymethyl.
- alkylene includes, for example, methylene, ethylene, propylene and the like.
- the various groups described above may be substituted.
- substituents include hydroxy, carboxy, sulfo, halogen, alkyl halide (haloalkyl, eg, CF 3 , CH 2 CF 3 , CH 2 CCl 3 ), nitro, nitroso, cyano, alkyl (eg, methyl, ethyl).
- alkenyl eg, vinyl
- alkynyl eg, ethynyl
- cycloalkyl eg, cyclopropyl, adamantyl
- cycloalkylalkyl eg, cyclohexylmethyl, adamantylmethyl
- cycloalkenyl eg, : Cyclopropenyl
- cyclylalkyl hydroxyalkyl (eg, hydroxymethyl, hydroxyethyl), alkoxyalkyl (eg, methoxymethyl, ethoxymethyl, ethoxyethyl), aryl (eg, phenyl, naphthyl), arylalkyl
- alkenyl eg, vinyl
- alkynyl eg, ethynyl
- cycloalkyl eg, cyclopropyl, adamantyl
- cycloalkylalkyl e
- the linker region (X a ) is represented by any of the following formulas (III-1) to (III-3). In each formula, n and m are the same as in the chemical formula (I).
- n and m are not particularly limited and are as described above.
- Their structures are shown in the following chemical formulas (III-1a), (III-2a) and (III-3a).
- the artificial sgRNA of the present invention comprises (1) the stem-loop 2 loop portion (GAAA) and / or (2) the linker region (UUAUC) of the natural sgRNA.
- the amino acid derivative linker (X b , Y) represented by the formula (I) can be substituted.
- an amino acid derivative linker (X c , X d ) represented by the above formula (I) is added to (3) 5 ′ end and / or (4) near the 3 ′ end of natural sgRNA and And / or can be inserted.
- the amino acid derivative linkers X b , Y, X c and X d may each independently be any amino acid derivative represented by the formula (I).
- the X b may be the formula (II)
- the Y is preferably, for example, a glycylglycine derivative linker represented by the formula (I-4) or a proline derivative linker represented by the formula (II), which is represented by the formula (I-4).
- the artificial sgRNA of the present invention may be one in which only the tetraloop portion of the natural sgRNA is replaced with the amino acid derivative linker (X a ). That is, in the following formula (A), Xb and Y are nucleotide linkers consisting of 1 to 5 arbitrary nucleotide residues, and Xc and Xd do not exist.
- X b and Y may remain the stem part of the stem-loop 2 of natural sgRNA (GAAA) and the linker region (UUAUC), respectively.
- GAA natural sgRNA
- UUAUC linker region
- Other nucleotide linkers can be substituted as long as they are retained. For example, it has been reported that Y can obtain equivalent or higher DSB activity even when only U is substituted from UUAUC.
- the artificial sgRNA of the present invention in which the loop part (GAAA) of stem-loop 2 is substituted with the amino acid derivative linker is superior in improving the stability in vivo. It is considered to be a useful tool for in vivo genome editing because it retains DNA cleavage activity in cells that is equal to or higher than that of natural sgRNA.
- the artificial sgRNA of the present invention has a linker region (UUAUC) in addition to the tetraloop portion of natural sgRNA and the loop portion of stem-loop 2 (GAAA), the amino acid derivative linker,
- X a , X b and Y in the formula (A) are simultaneously substituted with an amino acid derivative linker. There may be cases where it is not preferred.
- the amino acid derivative linker preferably the proline derivative linker represented by the formula (II), more preferably the formula (II), in the vicinity of the 5 ′ end and the 3 ′ end.
- two or more amino acid derivatives linker is introduced above or artificial type sgRNA is, X a only like the artificial type sgRNA amino acid derivative linker is introduced, when combined with Cas9, natural It can have the activity of cleaving target double-stranded DNA in cells, which is equal to or higher than that of type sgRNA.
- the nuclease resistance of sgRNA can be further improved, and the in vivo stability can be improved. The effect of improving the stability in vivo can be confirmed, for example, by conducting a resistance test against serum and / or nuclease in vitro.
- the artificial sgRNA of the present invention includes not only the nucleotide sequence represented by the formula (A) but also 1 to several (for example, 1, 2, 3, 4, 5, 6, 7, 8, (9 or 10) nucleotide sequence with substitutions, deletions, insertions or additions, and when combined with Cas9, target double-stranded DNA equivalent to or more than natural sgRNA Those having recognition ability (binding activity) are also included.
- the shortened sgRNA lacking the 3 ′ end and the stem-loop 2 and linker region of tracrRNA Significantly decreases DSB activity when combined with Cas9.
- natural sgRNA is adjacent not only to the tetraloop but also to 1 to 3 base pairs of the stem adjacent thereto and / or not only to the loop portion of stem-loop 2 1-4 base pairs of the stem is also represented by the amino acid derivative linker, preferably the proline derivative linker represented by the formula (II), more preferably the formula (II-8),
- the present invention also provides the following artificial sgRNA.
- the nucleotide residue constituting the artificial sgRNA of the present invention includes, for example, a sugar, a base, and a phosphate as constituent elements.
- Examples of the nucleotide residues include ribonucleotide residues and deoxyribonucleotide residues as described above.
- the ribonucleotide residue has, for example, a ribose residue as a sugar, and has adenine (A), guanine (G), cytosine (C) and U (uracil) as bases
- the deoxyribose residue is For example, it has a deoxyribose residue as a sugar and has adenine (A), guanine (G), cytosine (C) and thymine (T) as bases.
- nucleotide residue examples include an unmodified nucleotide residue and a modified nucleotide residue.
- each of the constituent elements is, for example, the same or substantially the same as that existing in nature, and preferably the same or substantially the same as that naturally occurring in the human body. .
- the modified nucleotide residue is, for example, a nucleotide residue obtained by modifying the unmodified nucleotide residue.
- the modified nucleotide residue for example, any of the constituent elements of the unmodified nucleotide residue may be modified.
- “modification” refers to, for example, substitution, addition and / or deletion of the component, substitution, addition and / or deletion of atoms and / or functional groups in the component, and is referred to as “modification”. be able to.
- modified nucleotide residue include naturally occurring nucleotide residues, artificially modified nucleotide residues, and the like. For example, Limbac et al.
- modified nucleosides of RNA Nucleic Acids Res. 22: 2183-2196
- the modified nucleotide residue may be, for example, a residue of an alternative to the nucleotide residue.
- ribophosphate skeleton examples include modification of a ribose-phosphate skeleton (hereinafter referred to as ribophosphate skeleton).
- a ribose residue can be modified.
- the ribose residue can be modified, for example, at the 2′-position carbon.
- a hydroxyl group bonded to the 2′-position carbon can be replaced with hydrogen, fluoro, or the like.
- the ribose residue can be replaced with a deoxyribose residue.
- the ribose residue can be substituted with, for example, a stereoisomer, and can be substituted with, for example, an arabinose residue.
- the ribophosphate skeleton may be substituted with a non-ribophosphate skeleton having a non-ribose residue and / or non-phosphate, for example.
- the non-ribophosphate skeleton include an uncharged body of the ribophosphate skeleton.
- the substitute for the nucleotide residue substituted with the non-ribophosphate skeleton include morpholino, cyclobutyl, pyrrolidine and the like.
- Other examples of the substitute include artificial nucleic acid monomer residues. Specific examples include PNA (peptide nucleic acid), LNA (Locked Nucleic Acid), ENA (2'-O, 4'-C-Ethylenebridged Nucleic Acids), and PNA is preferable.
- a phosphate group can be modified.
- the phosphate group closest to the sugar residue is called an ⁇ -phosphate group.
- the ⁇ -phosphate group is negatively charged, and the charge is evenly distributed over two oxygen atoms that are not bound to a sugar residue.
- the four oxygen atoms in the ⁇ -phosphate group in the phosphodiester bond between nucleotide residues, the two oxygen atoms that are non-bonded to the sugar residue are hereinafter referred to as “non-linking oxygen”.
- the two oxygen atoms bonded to the sugar residue are hereinafter referred to as “linking oxygen”.
- the ⁇ -phosphate group is preferably modified, for example, to be uncharged or to be asymmetric in the charge distribution in the non-bonded atoms.
- the phosphate group may replace the non-bonded oxygen, for example.
- the oxygen is, for example, S (sulfur), Se (selenium), B (boron), C (carbon), H (hydrogen), N (nitrogen), and OR (R is, for example, an alkyl group or an aryl group) It can be substituted with any atom, and is preferably substituted with S.
- both are preferably substituted, and more preferably, both are substituted with S.
- modified phosphate group examples include phosphorothioate, phosphorodithioate, phosphoroselenate, boranophosphate, boranophosphate ester, phosphonate hydrogen, phosphoramidate, alkyl or arylphosphonate, and phosphotriester.
- phosphorodithioate in which the two non-bonded oxygens are both substituted with S is preferable.
- the phosphate group may substitute, for example, the bonded oxygen.
- the oxygen may be substituted with any atom of S (sulfur), C (carbon) and N (nitrogen), for example.
- Examples of the modified phosphate group include a bridged phosphoramidate substituted with N, a bridged phosphorothioate substituted with S, and a bridged methylenephosphonate substituted with C.
- the binding oxygen substitution is preferably performed, for example, on at least one of the 5 ′ terminal nucleotide residue and the 3 ′ terminal nucleotide residue of the artificial sgRNA of the present invention. For the 'side, substitution with N is preferred.
- the phosphate group may be substituted with, for example, the phosphorus-free linker.
- the linker include siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioform acetal, form acetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethyl. Hydrazo, methyleneoxymethylimino and the like, preferably methylenecarbonylamino group and methylenemethylimino group.
- the artificial sgRNA of the present invention for example, at least one nucleotide residue at the 3 'end and the 5' end may be modified.
- the modification may be, for example, either the 3 'end or the 5' end, or both.
- the modification is, for example, as described above, and is preferably performed on the terminal phosphate group.
- the phosphate group may be modified entirely, or one or more atoms in the phosphate group may be modified. In the former case, for example, the entire phosphate group may be substituted or deleted.
- Examples of the modification of the terminal nucleotide residue include addition of other molecules.
- Examples of the other molecules include functional molecules such as a labeling substance and a protecting group as described above.
- Examples of the protecting group include S (sulfur), Si (silicon), B (boron), ester-containing groups, and the like.
- the other molecule may be added to the phosphate group of the nucleotide residue, for example, or may be added to the phosphate group or the sugar residue via a spacer.
- the terminal atom of the spacer can be added or substituted, for example, to the binding oxygen of the phosphate group or O, N, S or C of the sugar residue.
- the binding site of the sugar residue is preferably, for example, C at the 3 'position or C at the 5' position, or an atom bonded thereto.
- the spacer can be added or substituted at a terminal atom of a nucleotide substitute such as PNA.
- the spacer is not particularly limited.
- n is a positive integer
- n 3 or 6 is preferable.
- the molecule to be added to the terminal includes, for example, a dye, an intercalating agent (for example, acridine), a crosslinking agent (for example, psoralen, mitomycin C), a porphyrin (TPPC4, texaphyrin, suffirin), a polycyclic Aromatic hydrocarbons (eg phenazine, dihydrophenazine), artificial endonucleases (eg EDTA), lipophilic carriers (eg cholesterol, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis- O (hexadecyl) glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3- (oleoy
- the 5 ′ end may be modified with, for example, a phosphate group or a phosphate group analog.
- the phosphorylation may be, for example, 5 ′ monophosphate ((HO) 2 (O) PO-5 ′), 5 ′ diphosphate ((HO) 2 (O) POP (HO) (O) —O-5) '), 5' triphosphate ((HO) 2 (O) PO- (HO) (O) POP (HO) (O) -O-5 '), 5'-guanosine cap (7-methylated or non-methylated) Methylation, 7m-GO-5 '-(HO) (O) PO- (HO) (O) POP (HO) (O) -O-5'), 5'-adenosine cap (Appp), any modification Or an unmodified nucleotide cap structure (NO-5 '-(HO) (O) PO- (HO) (O) POP (HO) (O) -O-5'
- the base is not particularly limited.
- the base may be, for example, a natural base or a non-natural base.
- the base may be, for example, naturally derived or a synthetic product.
- As the base for example, a general base or a modified analog thereof can be used.
- Examples of the base include purine bases such as adenine and guanine, pyrimidine bases such as cytosine, uracil and thymine.
- Other examples of the base include inosine, thymine, xanthine, hypoxanthine, nubalarine, isoguanisine, and tubercidine.
- the base examples include alkyl derivatives such as 2-aminoadenine and 6-methylated purine; alkyl derivatives such as 2-propylated purine; 5-halouracil and 5-halocytosine; 5-propynyluracil and 5-propynylcytosine; -Azouracil, 6-azocytosine and 6-azothymine; 5-uracil (pseudouracil), 4-thiouracil, 5-halouracil, 5- (2-aminopropyl) uracil, 5-aminoallyluracil; 8-halogenated, aminated, Thiolated, thioalkylated, hydroxylated and other 8-substituted purines; 5-trifluoromethylated and other 5-substituted pyrimidines; 7-methylguanine; 5-substituted pyrimidines; 6-azapyrimidines; N-2, N -6 and O-6 substituted purines (2-aminopropyladenyl 5-
- the modified nucleotide residue may include, for example, a residue lacking a base, that is, an abasic ribophosphate skeleton.
- the modified nucleotide residues are, for example, US Provisional Application No. 60 / 465,665 (filing date: April 25, 2003) and International Application No. PCT / US04 / 07070 (filing date: 2004/3). The residues described on the 8th of May) can be used, and the present invention can incorporate these documents.
- the artificial sgRNA of the present invention may be a modified form in which any functional molecule is added via a non-nucleotide residue including an amino acid derivative linker, for example, by the method described in WO 2013/180038. it can.
- the method for synthesizing the artificial sgRNA of the present invention is not particularly limited, and conventionally known methods can be employed. Examples include the phosphoramidite method and the H-phosphonate method.
- a commercially available automatic nucleic acid synthesizer can be used.
- amidite is generally used.
- the amidite is not particularly limited, and commercially available amidites include, for example, RNA Phosphoramidates (2′-O-TBDMSi, trade name, Michisato Pharmaceutical), ACE amidite, TOM amidite, CEE amidite, CEM amidite, TEM amidite, etc. Can be given.
- the monomer of the present invention described later is preferably used in the synthesis of the linker region represented by the formula (I).
- the monomer of the present invention is a monomer for nucleic acid synthesis and has a structure represented by the following formula (IV).
- X 1 , X 2 , Y 1 , Y 2 , L 1 , L 2 and A are as defined in the above formula (I), and R 11 and R 21 are each independently a hydrogen atom, Group or phosphate protecting group.
- the protecting group is, for example, the same as described in the formula (I), and specific examples thereof include, for example, a dimethoxytrityl (DMTr) group, a TBDMS group, an ACE group, a TOM group, a CEE group, Examples include CEM group, TEM group, and silyl-containing group (group I) represented by the following formula (P1) or (P2). Among them, DMtr group and any of the silyl-containing groups are preferable.
- the phosphate protecting group can be represented by the following formula, for example. -P (OR 6 ) (NR 7 R 8 )
- R 6 is a hydrogen atom or an arbitrary substituent.
- the substituent R 6 is preferably, for example, a hydrocarbon group, and the hydrocarbon group may be substituted with an electron withdrawing group or may not be substituted.
- Substituent R 6 is, for example, halogen, haloalkyl, heteroaryl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, silyl, silyloxyalkyl, heterocyclylalkenyl, heterocyclylalkyl, heteroarylalkyl, and alkyl, alkenyl, alkynyl, aryl, Examples thereof include hydrocarbons such as arylalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl and the like, and may be substituted with an electron withdrawing group or may not be substituted.
- Specific examples of the substituent R 6 include a ⁇ -cyanoethyl group, a nitrophenylethyl group, and a methyl group.
- R 7 and R 8 are each a hydrogen atom or an arbitrary substituent, and may be the same or different.
- the substituents R 7 and R 8 are preferably, for example, a hydrocarbon group, and the hydrocarbon group may be further substituted with an arbitrary substituent or may not be substituted.
- the hydrocarbon group is, for example, the same as the enumeration for R 6 described above, and is preferably a methyl group, an ethyl group, or an isopropyl group.
- specific examples of —NR 7 R 8 include a diisopropylamino group, a diethylamino group, and an ethylmethylamino group.
- the substituents R 7 and R 8 are combined together with the nitrogen atom to which they are bonded (that is, —NR 7 R 8 is combined), and a nitrogen-containing ring (eg, piperidyl group, morpholino group, etc.) May be formed.
- a nitrogen-containing ring eg, piperidyl group, morpholino group, etc.
- phosphate protecting group examples include, for example, —P (OCH 2 CH 2 CN) (N (i-Pr) 2 ), —P (OCH 3 ) (N (i-Pr) 2 ), etc. II).
- i-Pr represents isopropyl.
- R 11 and R 21 are a hydrogen atom or a protecting group, and the other is a hydrogen atom or a phosphate protecting group.
- R 21 is preferably a hydrogen atom or the phosphate protecting group.
- R 2 is hydrogen It is preferably selected from atoms or said group II.
- R 21 is preferably a hydrogen atom or the protecting group.
- R 21 is , Preferably a hydrogen atom or the group I.
- monomers of the present invention include monomers described in WO 2013/103146, and monomers represented by the following formulas (IV-1) to (IV-3).
- R 11 and R 21 have the same meanings as the formula (IV), and n and m are each independently an integer of 0 to 30.
- the monomer of the present invention can be synthesized by, for example, a method described in WO 2013/103146 or a method described in Examples described later.
- CRISPR / Cas9 system The present invention also provides a CRISPR / Cas9 system comprising the above-described artificial sgRNA of the present invention combined with Cas9.
- Cas9 used in the present invention forms a complex with the artificial sgRNA of the present invention, and can recognize and bind to the target nucleotide sequence in the target double-stranded DNA and the adjacent proto-spacer adjacent motif (PAM).
- PAM proto-spacer adjacent motif
- as9 Cas9 derived from Streptococcus pyogenes
- PAM sequence NGG N is A, G, T, or C.
- Cas9 derived from Streptococcus thermophilus (StCas9; PAM sequence NNAGAAW), Cas9 derived from Neisseria meningitidis (MmCas9; PAM sequence NNNNGATT), etc., but there are few restrictions due to PAM SpCas9 is particularly preferred (substantially 2 bases and can theoretically be targeted almost anywhere on the genome).
- StCas9 Streptococcus thermophilus
- MmCas9 Cas9 derived from Neisseria meningitidis
- PAM sequence NNNNGATT Neisseria meningitidis
- Cas9 used in the present invention in addition to wild-type Cas9 capable of cleaving both strands of double-stranded DNA, those having nickase activity (nCas9) having inactivated the ability to cleave one strand can also be used.
- the 10th Asp residue is converted to an Ala residue
- the D10A mutant lacking the ability to cleave the opposite strand that forms a strand complementary to sgRNA, or the 840th His residue is Ala
- examples include, but are not limited to, H840A mutants that lack the ability to cleave strands that form a complementary strand with sgRNA converted at the residue.
- a double mutant (dCas9) lacking the ability to cleave both strands can also be used.
- dCas9 and nCas9 include, for example, fusing transcription regulators and chromatin modifiers to dCas9 / nCas9 to control transcription of target genes, or fusing fluorescent proteins to target gene loci.
- Cpf1 can also be used instead of Cas9.
- Cpf1 examples include Cpf1 (FnCpf1; PAM sequence NTT) derived from Francisella novicida, Cpf1 (AsCpf1; PAM sequence NTTT) derived from Acidaminococcus sp., Lachnospiraceae (Lachnospiraceae) bacterium) -derived Cpf1 (LbCpf1; PAM sequence NTTT) and the like, but are not limited thereto.
- Cpf1 FnCpf1; PAM sequence NTT
- Cpf1 AsCpf1; PAM sequence NTTT
- Lachnospiraceae Loachnospiraceae
- LbCpf1 Lachnospiraceae
- PAM sequence NTTT Lachnospiraceae
- a mutant lacking one or both strand cleavage activities can also be used.
- a mutant lacking the ability to cleave both strands with the 917th Asp residue converted to an Ala residue (D917A) or the 1006th Glu residue converted to an Ala residue (E1006A) dCpf1) can be used.
- the Cas9 used in the CRISPR / Cas9 system of the present invention may be in the form of a protein or in the form of mRNA that encodes it. Or the form of the expression vector containing DNA which codes Cas9 may be sufficient.
- Cas9 is provided in the form of a protein.
- Cas9 can be introduced into the cell in any form of protein, mRNA encoding the same, and expression vector containing the DNA encoding the same.
- the DNA encoding Cas9 can be cloned by, for example, amplifying by RT-PCR using total RNA or mRNA fraction prepared from cells producing the protein as a template. Mutant Cas9 is converted into the cloned Cas9-encoding DNA by using a site-directed mutagenesis method known per se (for example, in the case of Cas9, the 10th Asp). And the 840th His residue can be obtained by introducing a mutation so that it is converted with other amino acids.
- DNA encoding Cas9 can be constructed as DNA having codon usage suitable for expression in the host cell to be used, in combination with chemical synthesis or PCR method or Gibson Assembly method.
- CDS sequences that optimize SpCas9 for expression in eukaryotic cells are well known.
- the obtained DNA encoding Cas9 can be inserted downstream of the promoter of an appropriate expression vector depending on the host.
- the expression vector may be introduced by a known method (eg, lysozyme method, competent method, PEG method, CaCl 2 coprecipitation method, electroporation method, microinjection method, particle gun method, lipofection method, Agrobacterium method, etc.).
- the artificial sgRNA and Cas9 of the present invention can be preferably introduced into a host cell by the nucleofection method.
- SgRNA and Cas9 protein introduced (expressed) into the cell form a complex, which binds to the target sequence and generates DSB in the target gene.
- the DSB is repaired by non-homologous end joining (NHEJ), but a target gene is destroyed (knocked out) by a frameshift mutation caused by accidental insertion / deletion (indel) of a base.
- NHEJ non-homologous end joining
- indel accidental insertion / deletion
- co-introducing donor DNA having a target homologous sequence at both ends homologous recombination repair occurs, and base modification and gene insertion (knock-in) are possible.
- Example 1 Synthesis of sgRNA
- the sgRNA shown in Table 1 was synthesized by a nucleic acid synthesizer (The ABI Expedite® 8909 Nucleic Acid Synthesis System, Applied Biosystems) based on the phosphoramidite method.
- EMM amidite International Publication No. 2013/027843
- the amidite was deprotected according to a conventional method and purified by HPLC.
- the underlined portion is a guide region complementary to the target nucleotide sequence, and proline diamide amidite was introduced into P, lysine diamide amidite was introduced into K, and glycylglycine diamide amidite was introduced into X.
- Test Example 1 Evaluation of in vitro cleavage activity of sgRNA targeting KRAS gene Plasmid DNA (pCMV6- Entry-KRAS (G12V), OriGene Technologies) was reacted with restriction enzyme Tth111I (TaKaRa) according to the attached protocol. After completion of the reaction, the product was purified according to a conventional method, and dissolved in TE buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA) so as to have a final concentration of 100 ng / ⁇ L to obtain substrate DNA. The substrate DNA was mixed with sgRNA and Cas9 as follows using the reagents attached to Cas9 Nuclease, S.
- the substrate DNA was mixed with sgRNA and Cas9 as follows using the reagents attached to Cas9 Nuclease, S. pyogenes (New England Biolabs); 100 ng substrate DNA + 10 ng sgRNA + 0.3 pmol Cas9 (total volume 10 ⁇ L) This was incubated at 37 ° C. for 30 minutes, and further incubated at 70 ° C. for 10 minutes to inactivate Cas9. Thereafter, electrophoresis was performed, and band intensity was measured using a gel imaging system PXi4 (SYNGENE) after ethidium bromide staining. Based on the measurement results, the cutting efficiency was calculated by the following equation.
- Cleavage Efficiency sum of cleaved band intensities / (sum of the cleaved and uncleaved band intensities) The results are shown in FIG. All the artificial sgRNAs showed cleavage efficiency equal to or higher than that of natural sgRNA (SG-0017).
- the obtained crude product was purified by silica gel column chromatography (ethyl acetate, containing 0.05% pyridine). This reaction was performed twice to obtain the target compound (14) (0.85 g). The instrumental analysis value of the compound (14) is shown below.
- Example 6 Synthesis of sgRNA Compounds 5, 10, 15, 5a, 5b and 5c synthesized in Examples 2 to 5, proline diamide amidite, lysine diamide amidite, glycine diamide amidite, terephthalic acid diamide amidite, Using the glycylglycine diamide amidite, sgRNAs shown in Tables 2-1 to 4 were synthesized in the same manner as in Example 1. In the following sequences, the underlined portion is a guide region complementary to the target nucleotide sequence, and the amino acid derivative linker is indicated by an abbreviation as shown in Table 5.
- the substrate DNA was mixed with sgRNA and Cas9 as follows using the reagents attached to Cas9 Nuclease, S. pyogenes (New England Biolabs); 100 ng substrate DNA + 0.5 ng sgRNA + 0.3 pmol Cas9 (10 ⁇ L total volume) After incubation at 37 ° C for 15 minutes, Cas9 was inactivated by further incubation at 70 ° C for 10 minutes. Thereafter, electrophoresis was performed, and band intensity was measured using a gel imaging system PXi4 (SYNGENE) after ethidium bromide staining. Based on the measurement results, the cutting efficiency was calculated by the following equation.
- Cleavage Efficiency sum of cleaved band intensities / (sum of the cleaved and uncleaved band intensities)
- the results are shown in FIGS.
- the numerical value under the gel represents the cutting efficiency obtained by the above formula.
- the relative cleavage efficiency of the artificial sgRNA of this example when the cleavage efficiency of the natural sgRNA (SG-0001) as a reference example is set to 1 is shown in FIG.
- Many of the artificial sgRNAs of this example showed cleavage efficiency equal to or higher than that of the natural sgRNA as a reference example, and it was found that substitution with amino acid derivatives at each site was effective.
- FIG. 9 shows the relative cleavage efficiency of the artificial sgRNA of this example when the cleavage efficiency of the natural sgRNA (SG-0017) as a reference example is 1.
- the artificial sgRNA of this example showed a cleavage efficiency equal to or higher than that of the natural sgRNA as a reference example, and it was found that substitution with an amino acid derivative at each site was effective.
- the substrate DNA was mixed with sgRNA and Cas9 as follows using the reagents attached to Cas9 Nuclease, S. pyogenes (New England Biolabs); 100 ng substrate DNA + 0.5 ng sgRNA + 0.3 pmol Cas9 (10 ⁇ L total volume) After incubation at 37 ° C for 15 minutes, Cas9 was inactivated by further incubation at 70 ° C for 10 minutes. Thereafter, electrophoresis was performed, and band intensity was measured using a gel imaging system PXi4 (SYNGENE) after ethidium bromide staining. Based on the measurement results, the cutting efficiency was calculated by the following equation.
- FIG. 11 shows the relative cleavage efficiency of the artificial sgRNA of this example when the cleavage efficiency of the natural sgRNA (SG-0090) as a reference example is 1.
- the artificial sgRNA of this example showed a cleavage efficiency equal to or higher than that of the natural sgRNA as a reference example, and it was found that substitution with an amino acid derivative at each site was effective.
- Test Example 6 Evaluation of intracellular cleavage activity of sgRNA targeting BCL-2 gene
- Jurkat cells (2 ⁇ 10 5 cells) were collected in a microtube and washed with PBS, and then 6 ⁇ g GeneArt Platinum Cas9 Nuclease (Thermo Fisher Scientific) and 1.2 ⁇ g sgRNA were suspended in 10 ⁇ L of the test substance solution added to ReSuspension buffer R attached to Neon 10 ⁇ L tip (Thermo Fisher Scientific).
- the cell suspension was aspirated into a Neon 10 ⁇ L tip, and transfection was performed using an electroporator Neon (Thermo Fisher Scientific) under the conditions of Pulse Voltage 1700 V, Pulse Width 20 ms, Pulse Number 1 time.
- the obtained cells were seeded in 24-well dish (Thermo Fisher Scientific) using 500 ⁇ L of RPMI1640 Medium (Thermo Fisher Scientific) containing 10% Fetal Bovine Serum (MP Biomedicals). After culturing at 37 ° C. and 5% CO 2 for 48 hours, the cells were collected and washed with PBS, and then genomic DNA was purified using GeneArt (registered trademark) Genomic Cleavage Detection Kit (Thermo Fisher Scientific).
- GeneArt (Registered Trademark) Genomic Cleavage Detection Kit using a part of the genomic DNA obtained as a template and the primer set for human BCL-2 gene amplification: 5'-ATCAAGTGTTCCGCGTGATTGAAGA-3 '/ 5'-CTCACATCACCAAGTGCACCTACCC-3' PCR was performed according to the attached protocol. Using the obtained PCR product, a chromosome in-del detection reaction was performed according to the protocol attached to GeneArt (registered trademark) Genomic Cleavage Detection Kit, and then agarose gel electrophoresis was performed, and the gel imaging system PXi4 ( SYNGENE) was used to measure the band intensity.
- GeneArt registered trademark
- Test Example 7 Evaluation of intracellular cleavage activity of sgRNA targeting BRAF gene A-375 cells (5.6 ⁇ 10 4 cells) were collected in a microtube and washed with PBS, and then 6 ⁇ g GeneArt Platinum Cas9 Nuclease (Thermo Fisher Scientific) and 1.2 ⁇ g sgRNA were suspended in 10 ⁇ L of a test substance solution added to ReSuspension buffer R attached to Neon 10 ⁇ L tip (Thermo Fisher Scientific).
- the cell suspension was aspirated into a Neon 10 ⁇ L tip, and transfection was performed using an electroporator Neon (Thermo Fisher Scientific) under the conditions of Pulse Voltage 1400 V, Pulse Width 20 ms, Pulse Number 2 times.
- the obtained cells were seeded in 24-well dishes (Thermo Fisher Scientific) using 500 ⁇ L of Dulbecco's Modified Eagle's Medium (High Glucose) (Sigma Aldrich) containing 10% Fetal Bovine Serum (MP Biomedicals). After culturing at 37 ° C.
- Genomic Cleavage Detection Kit (Thermo Fisher Scientific). Using a part of the obtained genomic DNA as a template, a primer set for human BRAF gene amplification: 5'-CGCCCAGGAGTGCCAAGAGAATATC-3 '/ 5'-CAGCAGCATCTCAGGGCCAAAAAT-3' is attached to GeneArt (registered trademark) Genomic Cleavage Detection Kit PCR was performed according to the protocol.
- the relative cleavage efficiency of the artificial sgRNA of this example when the cleavage efficiency of the natural sgRNA (SG-0090) as a reference example is set to 1 is shown in FIG.
- the artificial sgRNAs of this Example some cells showed a cutting efficiency equal to or higher than that of the natural sgRNA as a reference example even in cells.
- the artificial sgRNA of the present invention can be easily synthesized at low cost, and, when combined with Cas9, retains DSB activity equal to or higher than that of natural sgRNA, while improving in vivo stability, It is useful for improving genome editing efficiency, especially genome editing efficiency in vivo.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
したがって、本発明の目的は、天然型RNAと同等もしくはそれ以上の活性を有し、かつ生体内での安定性が向上した新規な人工sgRNAを提供し、該人工sgRNAとCas9とを組み合わせることにより、より効率的なCRISPR/Cas9システムを提供することである。
特に、テトラループ部分のみならず、ステム-ループ2のループ部分もアミノ酸誘導体リンカーに置換した、2カ所にリンカーを導入したsgRNAでも、元のsgRNAと同等以上の細胞内でのDNA切断活性を有することが見出されたことは興味深い。そのような人工sgRNAは生体内での安定性改善効果がより大きいと考えられるからである。
[1](1)下式(A):
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
L1は、n個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
mは、0~30の整数であり;
nは、0~30の整数であり;
R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(I)であり、
Aは、任意の原子団であり、ただし、下式(Ia)は、アミノ酸またはペプチドである。)で表わされるアミノ酸誘導体リンカーであり、
式(A)中、Xb及びYは、それぞれ独立して、1ないし5個の任意のヌクレオチドリンカーであるか、あるいは、上記式(I)で表わされるアミノ酸誘導体リンカーであり、
前記Xb及びYは、それぞれ独立して、前記-OR1-または-OR2-を介して隣接するヌクレオチド残基に結合し、
式(A)中、Xc及びXdは、存在しても存在しなくてもよく、存在する場合、それぞれ独立して、前記式(I)で表わされるアミノ酸誘導体リンカーであり、
前記Xc及びXdは、それぞれ独立して、前記-OR1-または-OR2-を介して隣接するヌクレオチド残基に結合し、
式(A)中、(n)20は、それぞれ独立してA、G、CまたはUである20±5個のヌクレオチド残基からなるヌクレオチド配列である。]で表わされる、単一ガイドRNA、あるいは
(2)前記式(A)において、(n)20を除く領域で1ないし数個のヌクレオチド残基が置換、欠失、挿入もしくは付加され、かつCas9タンパク質と複合体を形成して前記(n)20に相補的な標的ヌクレオチド配列を含む二本鎖DNAを認識する活性を有する、単一ガイドRNA。
[2]前記式(Ia)のアミノ酸またはペプチドを構成するアミノ酸が、置換基または保護基を有していてもよい、グリシン、α-アラニン、アルギニン、アスパラギン、アスパラギン酸、システイン、シスチン、グルタミン、グルタミン酸、ヒスチジン、イソロイシン、ロイシン、リシン、ヒドロキシリシン、メチオニン、フェニルアラニン、セリン、トレオニン、チロシン、バリン、プロリン、4-ヒドロキシプロリン、トリプトファン、β-アラニン、1-アミノ-2-カルボキシシクロペンタン、アミノ安息香酸、アミノピリジンカルボン酸、および下記化学式(Ia2):
[3]前記Xaが、下式(I-1)~(I-7):
[4]前記Xaが、前記式(I-4)または(I-7)で表され、該式中、n=5およびm=4である、[3]記載の単一ガイドRNA。
[5]前記Xaが、前記式(I-1)で表され、該式中、n=5およびm=4である、または前記式(I-6)で表され、該式中、n=4およびm=4である、[3]記載の単一ガイドRNA。
[6]前記Xaが、下式(II):
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
R3は、環A上のC-3、C-4、C-5またはC-6に結合する水素原子または置換基であり;
L1は、n個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
lは、1または2であり;
mは、0~30の整数であり;
nは、0~30の整数であり;
環Aは、前記環A上のC-2以外の1個の炭素原子が、窒素、酸素または硫黄で置換されてもよく、
前記環A内に、炭素-炭素二重結合または炭素-窒素二重結合を含んでもよく、
R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(II)であり、
前記Xaは、-OR1-または-OR2-を介して、隣接するヌクレオチド残基に結合する。)で表される、[1]または[2]記載の単一ガイドRNA。
[7]前記Xaが、下式(II-1)~(II-9):
[8]前記Xaが、前記式(II-8)で表され、該式中、n=5およびm=4、n=7およびm=6、n=9およびm=8、またはn=11およびm=10である、[7]記載の単一ガイドRNA。
[9]前記Xaが、下式(III-1)~(III-3):
[10]前記各式中、n=5およびm=4である、[9]記載の単一ガイドRNA。
[11]前記Xb及びYが、それぞれ独立して、1ないし5個の任意のヌクレオチドリンカーである、[1]~[10]のいずれか一項に記載の単一ガイドRNA。
[12]前記Xc及びXdが存在しない、[11]記載の単一ガイドRNA。
[13]前記Xc及びXdが、それぞれ独立して、前記式(I)で表わされるアミノ酸誘導体リンカーである、[11]記載の単一ガイドRNA。
[14]前記Xc及びXdが、前記式(II)で表わされるアミノ酸誘導体リンカーである、[13]記載の単一ガイドRNA。
[15]前記Xc及びXdが、前記式(II-8)で表わされ、該式中、n=5およびm=4である、[14]記載の単一ガイドRNA。
[16]前記Xc及びXdが、前記式(I-1)、(I-4)、(I-7)及び(III-1)~(III-3)のいずれかで表わされ、該式中、n=5およびm=4であるか、あるいは、前記式(I-6)で表わされ、該式中、n=4およびm=4である、[13]記載の単一ガイドRNA。
[17]前記Xbが、前記式(I)で表されるアミノ酸誘導体リンカーである、[1]~[10]のいずれか一項に記載の単一ガイドRNA。
[18]前記Xbが、前記式(II)で表わされるアミノ酸誘導体リンカーである、[17]記載の単一ガイドRNA。
[19]前記Xbが、前記式(II-8)で表わされ、該式中、n=5およびm=4である、[18]記載の単一ガイドRNA。
[20]前記Xbが、前記式(I-1)、(I-4)、(I-7)及び(III-1)~(III-3)のいずれかで表わされ、該式中、n=5およびm=4であるか、あるいは、前記式(I-6)で表わされ、該式中、n=4およびm=4である、[17]記載の単一ガイドRNA。
[21]前記Yが、1ないし5個の任意のヌクレオチドリンカーである、[17]~[20]のいずれか一項に記載の単一ガイドRNA。
[22]前記Yが、前記式(I)で表されるアミノ酸誘導体リンカーである、[17]~[20]のいずれか一項に記載の単一ガイドRNA。
[23]前記Yが、前記式(I-4)で表され、該式中、n=5およびm=4である、[22]記載の単一ガイドRNA。
[24]前記Yが、前記式(II)で表されるアミノ酸誘導体リンカーである、[22]記載の単一ガイドRNA。
[25]前記Yが、前記式(II-8)で表され、該式中、n=5およびm=4、n=7およびm=6、n=9およびm=8、またはn=11およびm=10である、[24]記載の単一ガイドRNA。
[26]前記Yが、前記式(I-1)、(I-7)及び(III-1)~(III-3)のいずれかで表わされ、該式中、n=5およびm=4であるか、あるいは、前記式(I-6)で表わされ、該式中、n=4およびm=4である、[22]記載の単一ガイドRNA。
[27]前記Xaが、前記式(II-8)で表され、該式中、n=5およびm=4であり、かつ前記Xaに隣接するステムの1~3塩基対が欠失した、[7]記載の単一ガイドRNA。
[28]前記Xbに隣接するステムの1~4塩基対が欠失した、[19]記載の単一ガイドRNA。
[29]前記Xaが、前記式(II-8)で表され、該式中、n=5およびm=4であり、かつ前記Xaに隣接するステムの1~3塩基対が欠失した、[28]記載の単一ガイドRNA。
[30]前記式(A)で表される単一ガイドRNAであって、該式中、Xa、Xb及びYは1ないし5個の任意のヌクレオチドリンカーであり、Xc及びXdは存在せず、ステム-ループ1のループ部分(UA)もしくはステム-ループ3のループ部分(AGU)が、前記式(II-8)で表され、該式中、n=5およびm=4であるアミノ酸誘導体リンカーで置換されている、単一ガイドRNA。
[31][1]~[30]のいずれか一項に記載の単一ガイドRNAと、Cas9とを組み合わせてなる、CRISPR/Cas9システム。
[32]Cas9がStreptococcus pyogenes由来である、[31]記載のCRISPR/Cas9システム。
[33]Cas9が、タンパク質、それをコードするmRNAまたはそれをコードするDNAを含む発現ベクターの形態である、[31]または[32]記載のCRISPR/Cas9システム。
[34][31]~[33]のいずれか一項に記載のCRISPR/Cas9システムを、標的二本鎖DNAに接触させることを含む、該二本鎖DNAの認識方法。
[35]Cas9タンパク質が二本鎖DNA切断活性を有する、[34]記載の方法。
[36]前記二本鎖DNAの切断が細胞内で行われる、[35]記載の方法。
[37]標的遺伝子をノックアウトするための、[36]記載の方法。
[38]標的遺伝子内の塩基を改変するか、あるいは該遺伝子内に外因性遺伝子を挿入するための、[36]記載の方法。
[39]核酸分子合成用のモノマーであって、下記式(IV-1)~(IV-3):
[40]前記各式中、n=5およびm=4である、[39]記載のモノマー。
[41]核酸分子の製造方法であって、[39]又は[40]記載のモノマーを使用することを特徴とする、方法。
[42]前記核酸分子が、[1]~[26]のいずれか一項に記載の単一ガイドRNAである、[41]記載の方法。
[43]核酸分子の製造のための、[39]又は[40]記載のモノマーの使用。
[44]前記核酸分子が、[1]~[26]のいずれか一項に記載の単一ガイドRNAである、[43]記載の使用。
本発明は、下記式で示されるStreptococcus pyogenes由来のcrRNA及びtracrRNA:
をキメラ化(短鎖化及び一本鎖化)した下記単一ガイドRNA(天然型sgRNA)において、
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
L1は、n個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
mは、0~30の整数であり;
nは、0~30の整数であり;
R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(I)であり、
Aは、任意の原子団であり、ただし、下式(Ia)は、アミノ酸またはペプチドである。)で表わされるアミノ酸誘導体リンカーであり、
式(A)中、Xb及びYは、それぞれ独立して、1ないし5個の任意のヌクレオチドリンカーであるか、あるいは、上記式(I)で表わされるアミノ酸誘導体リンカーであり、
前記Xb及びYは、それぞれ独立して、前記-OR1-または-OR2-を介して隣接するヌクレオチド残基に結合し、
式(A)中、Xc及びXdは、存在しても存在しなくてもよく、存在する場合、それぞれ独立して、前記式(I)で表わされるアミノ酸誘導体リンカーであり、
前記Xc及びXdは、それぞれ独立して、前記-OR1-または-OR2-を介して隣接するヌクレオチド残基に結合し、
式(A)中、(n)20は、それぞれ独立してA、G、CまたはUである20±5個のヌクレオチド残基からなるヌクレオチド配列である。]で表わされる、単一ガイドRNA、あるいは
(2)前記式(A)において、(n)20を除く領域で1ないし数個のヌクレオチド残基が置換、欠失、挿入もしくは付加され、かつCas9タンパク質と複合体を形成して前記(n)20に相補的な標的ヌクレオチド配列を含む二本鎖DNAを切断する活性を有する、単一ガイドRNAである。
条件(1)
隣接するヌクレオチド残基の3’末端は、-OR2-を介して、隣接するヌクレオチド残基の5’末端は、-OR1-を介して、前記式(I)の構造と結合する。
条件(2)
隣接するヌクレオチド残基の3’末端は、-OR1-を介して、隣接するヌクレオチド残基の5’末端は、-OR2-を介して、前記式(I)の構造と結合する。
例えば、前記(I)または(Ia)中の原子団Aは、例えば、鎖式原子団、脂環式原子団、および芳香族性原子団からなる群から選択される少なくとも一つを含んでいても含んでいなくても良い。前記鎖式原子団は、特に限定されないが、例えば、アルキル、アルケニル、アルキニル、ハロアルキル、ヒドロキシアルキル、アルコキシアルキル、アミノアルキル、シリル、シリルオキシアルキル等が挙げられる。前記脂環式原子団は、特に限定されないが、例えば、シクロアルキル、シクロアルケニル、シクロアルキルアルキル、シクリルアルキル等が挙げられる。前記芳香族性原子団は、特に限定されないが、例えば、アリール、アリールアルキル、アルキルアリール、縮環系アリール、縮環系アリールアルキル、縮環系アルキルアリール等が挙げられる。また、前記式(I)または(Ia)中の原子団Aにおいて、前記各原子団は、さらに置換基または保護基を有していても有していなくても良い。前記置換基または保護基は、複数の場合は同一でも異なってもよい。前記置換基としては、例えば、前記Ra、Rb、RcおよびRdで例示した置換基が挙げられ、より具体的には、例えば、ハロゲン、ヒドロキシ、アルコキシ、アミノ、カルボキシ、スルホ、ニトロ、カルバモイル、スルファモイル、アルキル、アルケニル、アルキニル、ハロアルキル、アリール、アリールアルキル、アルキルアリール、シクロアルキル、シクロアルケニル、シクロアルキルアルキル、シクリルアルキル、ヒドロキシアルキル、アルコキシアルキル、アミノアルキル、シリル、シリルオキシアルキル、ピロールイル、イミダゾリル等があげられる。前記保護基は、例えば、前記Ra、Rb、RcおよびRdで例示した保護基と同様である。
R100は、任意の置換基であり、存在しても存在しなくてもよく、存在する場合は、1個でも複数でもよく、複数の場合は、互いに同一でも異なっていてもよい。R100における前記任意の置換基としては、例えば、前記Ra、Rb、RcおよびRdで例示した置換基が挙げられ、より具体的には、例えば、ハロゲン、ヒドロキシ、アルコキシ、アミノ、カルボキシ、スルホ、ニトロ、カルバモイル、スルファモイル、アルキル、アルケニル、アルキニル、ハロアルキル、アリール、アリールアルキル、アルキルアリール、シクロアルキル、シクロアルケニル、シクロアルキルアルキル、シクリルアルキル、ヒドロキシアルキル、アルコキシアルキル、アミノアルキル、シリル、シリルオキシアルキル、ピロールイル、イミダゾリル等があげられる。また、前記化学式(Ia2)の構造は、例えば、下記化学式(Ia3)であってもよい。
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
R3は、環A上のC-3、C-4、C-5またはC-6に結合する水素原子または置換基であり、
L1は、n個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換れていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
lは、1または2であり;
mは、0~30の整数であり;
nは、0~30の整数であり;
環Aは、前記環A上のC-2以外の1個の炭素原子が、窒素、酸素、硫黄で置換されてもよく、
前記環A内に、炭素-炭素二重結合または炭素-窒素二重結合を含んでもよく、
R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(II)であり、
前記Xaは、前記-OR1-または-OR2-を介して隣接するヌクレオチド残基に結合する。
条件(1)
隣接するヌクレオチド残基の3’末端は、-OR2-を介して、隣接するヌクレオチド残基の5’末端は、-OR1-を介して、前記式(II)の構造と結合する。
条件(2)
隣接するヌクレオチド残基の3’末端は、-OR1-を介して、隣接するヌクレオチド残基の5’末端は、-OR2-を介して、前記式(II)の構造と結合する。
あるいは、前記Xbとして、前記式(I-1)で表され、該式中、n=5およびm=4であるグリシン誘導体リンカー(Gly)、前記式(I-4)で表され、該式中、n=5およびm=4であるグリシルグリシン誘導体リンカー(GlyGly)、前記式(I-6)で表わされ、該式中、n=4およびm=4であるテレフタル酸誘導体リンカー(TP)、前記式(I-7)で表され、該式中、n=5およびm=4であるリシン誘導体リンカー(K)、(III-1)で表され、該式中、n=5およびm=4であるフェニルアラニン誘導体リンカー(F)、前記式(III-2)で表され、該式中、n=5およびm=4であるロイシン誘導体リンカー(L)、前記式(III-3)で表され、該式中、n=5およびm=4であるグルタミン酸誘導体リンカー(E)もまた好ましい。
前記Yとしては、例えば、前記式(I-4)で表されるグリシルグリシン誘導体リンカーや、前記式(II)で表されるプロリン誘導体リンカーが好ましく、前記式(I-4)で表され、該式中、n=5およびm=4であるグリシルグリシン誘導体リンカー(GlyGly)や、前記式(II-8)で表され、該式中、n=5およびm=4(P)、n=7およびm=6(P13)、n=9およびm=8(P14)、またはn=11およびm=10(P15)であるプロリン誘導体リンカーがより好ましい。
あるいは、前記Yとして、前記式(I-1)で表され、該式中、n=5およびm=4であるグリシン誘導体リンカー(Gly)、前記式(I-6)で表わされ、該式中、n=4およびm=4であるテレフタル酸誘導体リンカー(TP)、前記式(I-7)で表され、該式中、n=5およびm=4であるリシン誘導体リンカー(K)、(III-1)で表され、該式中、n=5およびm=4であるフェニルアラニン誘導体リンカー(F)、前記式(III-2)で表され、該式中、n=5およびm=4であるロイシン誘導体リンカー(L)、前記式(III-3)で表され、該式中、n=5およびm=4であるグルタミン酸誘導体リンカー(E)もまた好ましい。
前記Xc及びXdとしては、例えば、それぞれ独立して、前記式(II)で表されるプロリン誘導体リンカーであることが好ましく、前記式(II-8)で表され、該式中、n=5およびm=4であるプロリン誘導体リンカー(P)であることがより好ましい。
あるいは、前記Xc及びXdとして、前記式(I-1)で表され、該式中、n=5およびm=4であるグリシン誘導体リンカー(Gly)、前記式(I-4)で表され、該式中、n=5およびm=4であるグリシルグリシン誘導体リンカー(GlyGly)、前記式(I-6)で表わされ、該式中、n=4およびm=4であるテレフタル酸誘導体リンカー(TP)、前記式(I-7)で表され、該式中、n=5およびm=4であるリシン誘導体リンカー(K)、(III-1)で表され、該式中、n=5およびm=4であるフェニルアラニン誘導体リンカー(F)、前記式(III-2)で表され、該式中、n=5およびm=4であるロイシン誘導体リンカー(L)、前記式(III-3)で表され、該式中、n=5およびm=4であるグルタミン酸誘導体リンカー(E)もまた好ましい。
あるいは、ステム-ループ2のループ部分(GAAA)が、前記式(I-1)で表され、該式中、n=5およびm=4であるグリシン誘導体リンカー(Gly)、前記式(I-4)で表され、該式中、n=5およびm=4であるグリシルグリシン誘導体リンカー(GlyGly)、前記式(I-6)で表わされ、該式中、n=4およびm=4であるテレフタル酸誘導体リンカー(TP)、前記式(I-7)で表され、該式中、n=5およびm=4であるリシン誘導体リンカー(K)、(III-1)で表され、該式中、n=5およびm=4であるフェニルアラニン誘導体リンカー(F)、前記式(III-2)で表され、該式中、n=5およびm=4であるロイシン誘導体リンカー(L)、又は前記式(III-3)で表され、該式中、n=5およびm=4であるグルタミン酸誘導体リンカー(E)に置換したものも、また好ましい。
天然型sgRNAのテトラループ部分に加えて、ステム-ループ2のループ部分(GAAA)が、前記アミノ酸誘導体リンカーに置換した本発明の人工sgRNAは、生体内での安定性改善効果により優れていると考えられ、しかも天然型sgRNAと同等以上の細胞内でのDNA切断活性を保持するので、in vivoゲノム編集のツールとして特に有用である。
あるいは、リンカー領域(UUAUC)が、前記式(I-1)で表され、該式中、n=5およびm=4であるグリシン誘導体リンカー(Gly)、前記式(I-4)で表され、該式中、n=5およびm=4であるグリシルグリシン誘導体リンカー(GlyGly)、前記式(I-6)で表わされ、該式中、n=4およびm=4であるテレフタル酸誘導体リンカー(TP)、前記式(I-7)で表され、該式中、n=5およびm=4であるリシン誘導体リンカー(K)、(III-1)で表され、該式中、n=5およびm=4であるフェニルアラニン誘導体リンカー(F)、前記式(III-2)で表され、該式中、n=5およびm=4であるロイシン誘導体リンカー(L)、又は前記式(III-3)で表され、該式中、n=5およびm=4であるグルタミン酸誘導体リンカー(E)に置換したものも、また好ましい。
但し、Cas9と組み合わせた場合の、細胞内でのDNA切断活性を考慮すると、本発明の人工sgRNAとしては、前記式(A)中のXa、Xb及びYが同時にアミノ酸誘導体リンカーに置換していないものが好ましい場合があり得る。
あるいは、5’末端及び3’末端近傍に、前記式(I-1)で表され、該式中、n=5およびm=4であるグリシン誘導体リンカー(Gly)、前記式(I-4)で表され、該式中、n=5およびm=4であるグリシルグリシン誘導体リンカー(GlyGly)、前記式(I-6)で表わされ、該式中、n=4およびm=4であるテレフタル酸誘導体リンカー(TP)、前記式(I-7)で表され、該式中、n=5およびm=4であるリシン誘導体リンカー(K)、(III-1)で表され、該式中、n=5およびm=4であるフェニルアラニン誘導体リンカー(F)、前記式(III-2)で表され、該式中、n=5およびm=4であるロイシン誘導体リンカー(L)、又は前記式(III-3)で表され、該式中、n=5およびm=4であるグルタミン酸誘導体リンカー(E)が、それぞれ付加及び挿入したものも、また好ましい。
天然型sgRNAのテトラループ部分に加えて、5’末端及び3’末端近傍に、前記アミノ酸誘導体リンカー、好ましくは、前記式(II)で表されるプロリン誘導体リンカー、より好ましくは、前記式(II-8)で表され、該式中、n=5およびm=4であるプロリン誘導体リンカー(P)が、それぞれ付加及び挿入した本発明の人工sgRNAは、生体内での安定性改善や自然免疫応答の亢進による副作用軽減効果により優れていると考えられ、しかも天然型sgRNAと同等以上の細胞内でのDNA切断活性を保持するので、in vivoゲノム編集のツールとして特に有用である。
また、テトラループや、tracrRNAのステム-ループ2、リンカー領域、sgRNAの両末端を修飾せずとも、tracrRNAのステム-ループ1もしくはステム-ループ3のループ部分を、前記アミノ酸誘導体リンカー、好ましくは、前記式(II)で表されるプロリン誘導体リンカー、より好ましくは、前記式(II-8)で表され、該式中、n=5およびm=4であるプロリン誘導体リンカー(P)に置換することによっても、Cas9と組み合わせた場合に、良好なDSB活性を保持させることができる。
従って、本発明はまた、以下の人工sgRNAを提供する。
(a)前記式(A)で表されるsgRNAであって、
(i)式中Xaが、前記式(II-8)で表され、該式中、n=5およびm=4であり、かつXaに隣接するステムの1~3塩基対が欠失した、及び/又は
(ii)式中Xbが、前記式(II-8)で表され、該式中、n=5およびm=4であり、かつXbに隣接するステムの1~4塩基対が欠失した、
該sgRNA。
(b)前記式(A)で表されるsgRNAであって、該式中、Xa、Xb及びYは1ないし5個の任意のヌクレオチドリンカーであり、Xc及びXdは存在せず、ステム-ループ1のループ部分(UA)もしくはステム-ループ3のループ部分(AGU)が、前記式(II-8)で表され、該式中、n=5およびm=4であるアミノ酸誘導体リンカーで置換されている、該sgRNA。
本発明の人工sgRNAの合成方法は、特に制限されず、従来公知の方法が採用できる。例えば、ホスホロアミダイト法およびH-ホスホネート法等があげられる。前記化学合成法は、例えば、市販の自動核酸合成機を使用可能である。前記化学合成法は、一般に、アミダイトが使用される。前記アミダイトは、特に制限されず、市販のアミダイトとして、例えば、RNA Phosphoramidites(2’-O-TBDMSi、商品名、三千里製薬)、ACEアミダイト、TOMアミダイト、CEEアミダイト、CEMアミダイト、TEMアミダイト等があげられる。本発明の人工sgRNAについては、例えば、前記式(I)で表わされるリンカー領域の合成の際、後述する本発明のモノマーを使用することが好ましい。
本発明のモノマーは、核酸合成用のモノマーであって、下記式(IV)の構造を有することを特徴とする。
-P(OR6)(NR7R8)
前記式において、R6は、水素原子または任意の置換基である。置換基R6は、例えば、炭化水素基が好ましく、前記炭化水素基は、電子吸引基で置換されていてもよいし、置換されていなくてもよい。置換基R6は、例えば、ハロゲン、ハロアルキル、ヘテロアリール、ヒドロキシアルキル、アルコキシアルキル、アミノアルキル、シリル、シリルオキシアルキル、ヘテロシクリルアルケニル、ヘテロシクリルアルキル、ヘテロアリールアルキル、および、アルキル、アルケニル、アルキニル、アリール、アリールアルキル、シクロアルキル、シクロアルケニル、シクロアルキルアルキル、シクリルアルキル等の炭化水素等があげられ、さらに、電子吸引基で置換されていてもよいし、置換されていなくてもよい。置換基R6は、具体的には、例えば、β-シアノエチル基、ニトロフェニルエチル基、メチル基等があげられる。
本発明はまた、上記本発明の人工sgRNAとCas9とを組み合わせてなる、CRISPR/Cas9システムを提供する。
本発明で使用されるCas9は、本発明の人工sgRNAと複合体を形成して、標的二本鎖DNA中の標的ヌクレオチド配列とそれに隣接するproto-spacer adjacent motif(PAM)を認識し結合し得る限り、特に制限はないが、好ましくはStreptococcus pyogenes由来のCas9(SpCas9; PAM配列NGG(NはA、G、T又はC。以下同じ))、本発明の人工sgRNAと複合体を形成し得る限り、ストレプトコッカス・サーモフィラス(Streptococcus thermophilus)由来のCas9(StCas9; PAM配列NNAGAAW)、ナイセリア・メニンギチジス(Neisseria meningitidis)由来のCas9(MmCas9; PAM配列NNNNGATT)等を使用することもできるが、PAMによる制約が少ないSpCas9が特に好ましい(実質2塩基であり、理論上ゲノム上のほぼどこでも標的化することができる)。本発明で用いられるCas9としては、二本鎖DNAの両方の鎖を切断できる野生型Cas9に加え、一方の鎖の切断能を失活したニッカーゼ活性を有するもの(nCas9)も使用可能である。例えば、SpCas9の場合、10番目のAsp残基がAla残基に変換した、sgRNAと相補鎖を形成する鎖の反対鎖の切断能を欠くD10A変異体、あるいは、840番目のHis残基がAla残基で変換した、sgRNAと相補鎖を形成する鎖の切断能を欠くH840A変異体が挙げられるが、これらに限定されない。さらに、使用目的によっては、両方の鎖の切断能を欠く二重変異体(dCas9)を用いることもできる。dCas9やnCas9を用いる具体的な実施態様としては、例えば、dCas9/nCas9に転写調節因子やクロマチン修飾因子を融合させ、標的遺伝子の転写を制御したり、あるいは、蛍光タンパク質を融合させて標的遺伝子座を可視化(ライブイメージング)することなどが挙げられるが、それらに限定されない。
また、Cas9の代わりにCpf1を用いることもできる。Cpf1としては、例えば、フランシセラ・ノヴィシダ(Francisella novicida)由来のCpf1(FnCpf1; PAM配列NTT)、アシダミノコッカス sp.(Acidaminococcus sp.)由来のCpf1(AsCpf1;PAM配列NTTT)、ラクノスピラ科細菌(Lachnospiraceae bacterium)由来のCpf1(LbCpf1; PAM配列NTTT)等が挙げられるが、それらに限定されない。Cpf1の場合も同様に、一方もしくは両方の鎖の切断活性を欠く変異体を用いることもできる。例えば、FnCpf1の場合、917番目のAsp残基がAla残基(D917A)に、あるいは1006番目のGlu残基がAla残基(E1006A)に変換した、両方の鎖の切断能を欠く変異体(dCpf1)を用いることができる。
得られたCas9をコードするDNAは、宿主に応じて、適当な発現ベクターのプロモーターの下流に挿入することができる。発現ベクターの導入は、宿主の種類に応じ、公知の方法(例えば、リゾチーム法、コンピテント法、PEG法、CaCl2共沈殿法、エレクトロポレーション法、マイクロインジェクション法、パーティクルガン法、リポフェクション法、アグロバクテリウム法など)に従って実施することができる。
表1に示すsgRNAを、ホスホロアミダイト法に基づき、核酸合成機(The ABI Expedite(R) 8909 Nucleic Acid Synthesis System,Applied Biosystems)により合成した。前記合成には、RNAアミダイトとしてEMMアミダイト(国際公開第2013/027843号)を用いた(以下同様)。前記アミダイトの脱保護は定法に従って行い、HPLCにより精製した。下記配列中、下線部は標的ヌクレオチド配列に相補的なガイド領域であり、Pにはプロリンジアミドアミダイトを、Kにはリジンジアミドアミダイトを、Xにはグリシルグリシンジアミドアミダイトをそれぞれ導入した。
ヒトKRAS遺伝子(GenBank accession No. NM_004985.3)のG12V変異を有する配列(NCBI Refference Sequence NP_0049762)を組み込んだプラスミドDNA(pCMV6-Entry-KRAS(G12V),OriGene Technologies)を、制限酵素Tth111I(TaKaRa)と添付のプロトコールに従い反応させた。反応終了後定法に従い精製し、終濃度100 ng/μLとなるようにTEバッファー(10 mM Tris-HCl, pH8,1 mM EDTA)に溶解し基質DNAとした。
上記基質DNAを、Cas9 Nuclease, S. pyogenes (New England Biolabs)に添付の試薬を用いてsgRNAおよびCas9と以下のように混合した;
100 ng 基質DNA + 10 ng sgRNA + 0.3 pmol Cas9(全量10μL)
これを37℃で30分間インキュベーションした後、さらに70℃で10分間インキュベーションしCas9を失活させた。その後電気泳動を行い、エチジウムブロマイド染色後ゲルイメージングシステムPXi4(SYNGENE社)を用いバンド強度を測定した。
測定結果を基に、下記の等式により 切断効率を算出した。
Cleavage Efficiency=sum of cleaved band intensities/(sum of the cleaved and uncleaved band intensities)
結果を図1に示す。いずれの人工sgRNAも、天然型sgRNA(SG-0001)と同等の切断効率を示した。
ヒトBCL-2遺伝子(GenBank accession No. NM_000633)を組み込んだプラスミドDNA(pCAGGS-hbcl-2,Iwahashi et.al., Nature, vol 390,pp414-417, 1997)を、制限酵素HindIII(TaKaRa)と添付のプロトコールに従い反応させた。反応終了後定法に従い精製し、終濃度100 ng/μLとなるようにTEバッファー(10 mM Tris-HCl, pH8,1 mM EDTA)に溶解し基質DNAとした。
上記基質DNAを、Cas9 Nuclease, S. pyogenes (New England Biolabs)に添付の試薬を用いてsgRNAおよびCas9と以下のように混合した;
100 ng 基質DNA + 10 ng sgRNA + 0.3 pmol Cas9(全量10μL)
これを37℃で30分間インキュベーションした後、さらに70℃で10分間インキュベーションしCas9を失活させた。その後電気泳動を行い、エチジウムブロマイド染色後ゲルイメージングシステムPXi4(SYNGENE社)を用いバンド強度を測定した。
測定結果を基に、下記の等式により 切断効率を算出した。
Cleavage Efficiency=sum of cleaved band intensities/(sum of the cleaved and uncleaved band intensities)
結果を図2に示す。いずれの人工sgRNAも、天然型sgRNA(SG-0017)と同等もしくはそれ以上の切断効率を示した。
下記スキームに従い、化合物(5)を合成した。
Fmoc-フェニルアラニン(3.0 g, 7.7 mmol)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)(1.78 g, 9.3 mmol)、1-ヒドロキシベンゾトリアゾール一水和物(HOBt)(2.51 g, 18.6 mmol)のアセトニトリル溶液(100 mL)に、4-アミノ-1-ブタノール(0.83 g, 9.3 mmol)を加えて室温で一晩撹拌した。反応終了後、減圧下溶媒留去した。残渣にジクロロメタンを加えて、飽和炭酸水素ナトリウム水溶液で2回、飽和塩化ナトリウム水溶液で1回洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮し、目的化合物(1)の粗生成物(4.1 g)を得た。
化合物(1)(4.1 g, 8.9 mmol)をピリジンで共沸し、真空乾燥させた。ピリジン(80 mL)に溶解させ、4,4’-ジメトキシトリチルクロライド(4.54 g, 13.4 mmol)を加えて室温にて一晩撹拌した。反応終了後、メタノールを加えて30分間撹拌し、減圧下溶媒留去した。残渣に酢酸エチルを加えて、飽和炭酸水素ナトリウム水溶液で2回、飽和塩化ナトリウム水溶液で1回洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮し、目的化合物(2)の粗生成物(9.8 g)を得た。
化合物(2)(9.8 g, 12.9 mmol)にN,N-ジメチルホルムアミド(50 mL)及びピペリジン(8.9 mL)を室温で加え、室温で一晩撹拌した。反応終了後、減圧下溶媒留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ジクロロメタン:メタノール=20:1、0.05%ピリジン含有)で精製し、目的化合物(3)(3.1 g, 3段階収率74%)を得た。
化合物(3)(3.1 g, 5.8 mmol)をピリジンで共沸し、真空乾燥させた。アルゴン雰囲気下で6-ヒドロキシヘキサン酸(0.91 g, 6.9 mmol)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)(1.32 g, 6.9 mmol)、1-ヒドロキシベンゾトリアゾール一水和物(HOBt)(1.87 g, 13.8 mmol)、及びジクロロメタン(40 mL)を室温で加え、10分間撹拌した後、トリエチルアミン(2.1 g, 20.7 mmol)を加え、室温で一晩撹拌した。得られた残渣にジクロロメタンを加え、飽和重曹水で2回、飽和塩化ナトリウム水溶液で洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:2、0.05%ピリジン含有)で精製し、目的化合物(4)(2.0 g, 収率53 %)を得た。以下に、化合物(4)の機器分析値を示す。
化合物(4):
1H-NMR(500 MHz, CDCl3) δ: 7.41-7.39(2H, m), 7.30-7.16(12H, m), 6.84-6.80(4H, m), 6.26(1H, d, J=7.4Hz), 5.71-5.69(1H, m), 4.57-4.52(1H, m), 3.79(6H, s), 3.64-3.58(2H, m), 3.18-3.15(1H, m), 3.09-2.93(5H, m), 2.19-2.16(2H, m), 1.64-1.58(2H, m), 1.56-1.50(2H, m), 1.46-1.39(4H, m), 1.36-1.30(2H, m).
化合物(4)(2.0 g, 3.1 mmol)をピリジンで共沸し、真空乾燥させた。つぎに、アセトニトリル(4 mL)とジイソプロピルアンモニウムテトラゾリド(0.63 g, 3.7 mmol)を加え、さらに2-シアノエチル-N,N,N’,N’-テトライソプロピルホスホロジアミダイト(1.1 g, 3.7 mmol)を加え、40℃にて2時間撹拌した。反応終了後、減圧下溶媒留去し、酢酸エチルを加えて飽和炭酸水素ナトリウム水溶液で2回、飽和塩化ナトリウム水溶液で1回ずつ洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:1、0.1%トリエチルアミン含有)で精製し、目的化合物(5)(2.4 g, 純度97.5%, 収率92%)を得た。
化合物(5)の機器分析値を示す。
化合物(5):
1H-NMR(500 MHz, CDCl3) δ: 7.41-7.40(2H, m), 7.33-7.16(12H, m), 6.86-6.80(4H, m), 6.28(1H, d, J=7.7 Hz), 5.77(1H, t, J=6.0 Hz), 4.58-4.54(1H, m), 3.87-3.80(1H, m), 3.79-3.74(1H, m), 3.78(6H, s), 3.67-3.53(4H, m), 3.21-3.15(1H, m), 3.10-2.94(5H, m), 2.62(2H, t, J=6.4 Hz), 2.18-2.12(2H, m), 1.64-1.55(4H, m), 1.46-1.39(4H, m), 1.36-1.31(2H, m), 1.17(12H, m).
31P-NMR (202 MHz, CDCl3) δ: 147.95, 147.91
ESI-Mass:871.49 [M+H2O+H]+
下記スキームに従い、化合物(10)を合成した。
Fmoc-ロイシン(3.0 g, 8.5 mmol)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)(1.95 g, 10.2 mmol)、1-ヒドロキシベンゾトリアゾール一水和物(HOBt)(2.75 g, 20.4 mmol)のアセトニトリル溶液(90 mL)に、4-アミノ-1-ブタノール(0.91 g, 10.2 mmol)を加えて室温で一晩撹拌した。反応終了後、減圧下溶媒留去した。残渣にジクロロメタンを加えて、飽和炭酸水素ナトリウム水溶液で2回、飽和塩化ナトリウム水溶液で1回洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮し、目的化合物(6)の粗生成物(4.42 g)を得た。
化合物(6)(4.42 g, 10.4 mmol)をピリジンで共沸し、真空乾燥させた。ピリジン(80 mL)に溶解させ、4,4’-ジメトキシトリチルクロライド(5.29 g, 15.6 mmol)を加えて室温にて一晩撹拌した。反応終了後、メタノールを加えて30分間撹拌し、減圧下溶媒留去した。残渣に酢酸エチルを加えて、飽和炭酸水素ナトリウム水溶液で2回、飽和塩化ナトリウム水溶液で1回洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮し、目的化合物(7)の粗生成物(9.51 g)を得た。
化合物(7)(9.51 g, 13.1 mmol)にN,N-ジメチルホルムアミド(40 mL)及びピペリジン(9.0 mL)を室温で加え、室温で一晩撹拌した。反応終了後、減圧下溶媒留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ジクロロメタン:メタノール=30:1、0.05%ピリジン含有、およびクロロメタン:メタノール=40:1、0.05%ピリジン含有)で精製し、目的化合物(8)(3.89 g, 3段階収率91%)を得た。
化合物(8)(3.89 g, 7.7 mmol)をピリジンで共沸し、真空乾燥させた。アルゴン雰囲気下で6-ヒドロキシヘキサン酸(1.22 g, 9.2 mmol)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)(1.77 g, 9.2 mmol)、1-ヒドロキシベンゾトリアゾール一水和物(HOBt)(2.50 g, 18.5 mmol)、及びジクロロメタン(50 mL)を室温で加え、10分間撹拌した後、トリエチルアミン(2.81 g, 27.7 mmol)を加え、室温で一晩撹拌した。得られた残渣にジクロロメタンを加え、飽和重曹水で2回、飽和塩化ナトリウム水溶液で洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:4、0.05%ピリジン含有)で精製し、目的化合物(9)(3.80 g, 収率80 %)を得た。以下に、化合物(9)の機器分析値を示す。
化合物(9):
1H-NMR(500 MHz, CDCl3) δ: 7.42-7.41(2H, m), 7.31-7.27(6H, m), 7.21-7.18(1H, m),6.83-6.80(4H, m), 6.21(1H, t, J=5.7 Hz), 6.05(1H, d, J=8.3 Hz), 4.41-4.36(1H, m), 3.78(6H, s), 3.64-3.59(2H, m), 3.31-3.15(2H, m), 3.06(2H, t, J=6.0 Hz), 2.20(2H, t, J=7.4 Hz), 1.78(1H, t, J=5.5 Hz), 1.68-1.47(10H, m), 1.40-1.34(2H, m), 0.93-0.91(6H, m).
化合物(9)(3.80 g, 6.1 mmol)をピリジンで共沸し、真空乾燥させた。つぎに、アセトニトリル(7.6 mL)とジイソプロピルアンモニウムテトラゾリド(1.26 g, 7.4 mmol)を加え、さらに2-シアノエチル-N,N,N’,N’-テトライソプロピルホスホロジアミダイト(2.22 g, 7.4 mmol)を加え、40℃にて2時間撹拌した。反応終了後、減圧下溶媒留去し、酢酸エチルを加えて飽和炭酸水素ナトリウム水溶液で2回、飽和塩化ナトリウム水溶液で1回ずつ洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:1、0.1%トリエチルアミン含有)で精製し、目的化合物(10)(4.80 g, 純度97.5%, 収率95.4%)を得た。以下に、化合物(10)の機器分析値を示す。
化合物(10):
1H-NMR(500 MHz, CDCl3) δ: 7.42-7.40(2H, m), 7.31-7.26(6H, m), 7.21-7.18(1H, m), 6.83-6.81(4H, m), 6.29(1H, t, J=5.6 Hz), 6.09(1H, d, J=8.5 Hz), 4.42-4.37(1H, m), 3.87-3.74(2H, m), 3.78(6H, s), 3.68-3.51(4H, m), 3.29-3.23(1H, m), 3.19-3.14(1H, m), 3.06(2H, t, J=5.7 Hz), 2.62(2H, t, J=6.2 Hz), 2.19(2H, t, J=8.0 Hz), 1.69-1.50(8H, m), 1.40-1.35(2H, m), 1.30-1.21(2H, m), 1.17(12H, m), 0.94-0.91(6H, m).
31P-NMR (202 MHz, CDCl3) δ: 147.95
ESI-Mass:841.47 [M+Na]+
下記スキームに従い、化合物(15)を合成した。
6-ヒドロキシヘキサン酸(1.00 g, 7.6 mmol)とジメチルアミノピリジン(DMAP)(92 mg, 0.8 mmol)のピリジン溶液(25 ml)に4,4’-ジメトキシトリチルクロライド(2.6 g, 7.6 mmol)を加えて室温にて5時間撹拌した。TLCにて原料の消失を確認した後、メタノールを加えて30分間撹拌した。減圧下溶媒留去し、ジクロロメタンを加えて、飽和炭酸水素ナトリウム水溶液で3回洗浄、飽和食塩水で1回洗浄した。有機層を硫酸ナトリウムにて乾燥後、減圧濃縮し、ヘキサンを用いてトリチュレーションを行った。減圧乾燥し、油状粗生成物を得た。その油状粗生成物にジクロロメタン(32 mL)を加え、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)(2.48 g, 13.0 mmol)、N-ヒドロキシコハク酸イミド(1.49 g, 13.0 mmol)を加えて室温にて一晩撹拌した。反応終了後、減圧下溶媒留去し、酢酸エチルを加えて、飽和炭酸水素ナトリウム溶液で3回洗浄、飽和食塩水で1回洗浄した。有機層を硫酸ナトリウムで乾燥後、減圧下溶媒留去し、目的化合物(11)の粗生成物(3.40 g)を得た。
Boc-グルタミン酸(OMe)(2.0 g, 7.7 mmol)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)(1.76 g, 9.2 mmol)、1-ヒドロキシベンゾトリアゾール一水和物(HOBt)(2.48 g, 18.4 mmol)のアセトニトリル溶液(40 mL)に、4-アミノ-1-ブタノール(0.82 g, 9.2 mmol)を加えて室温で一晩撹拌した。反応終了後、減圧下溶媒留去した。残渣にジクロロメタンを加えて、飽和炭酸水素ナトリウム水溶液で2回、飽和塩化ナトリウム水溶液で1回洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮し、目的化合物(12)の粗生成物(2.30 g)を得た。
化合物(12)(2.30 g, 6.9 mmol)に1,4-ジオキサン(23 ml)を加え溶解し、0℃で塩酸(2.3 ml)を加え、室温に戻して30分間撹拌した。反応終了後、減圧下溶媒留去し、イソプロピルエーテルを用いてトリチュレーションを行い減圧乾燥させ、目的化合物(13)の粗生成物(2.06 g)を得た。
化合物(13)(0.93 g, 4.0 mmol)のDMF溶液(9 ml)にトリエチルアミン(0.61 g, 6.0 mmol)、化合物(11)(2.34 g, 4.4 mmol)のDMF溶液(9 ml)を加えて室温で一晩撹拌した。反応終了後、減圧下溶媒留去し、残渣にジクロロメタンを加え、飽和食塩水で3回洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧下溶媒留去した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(酢酸エチル、0.05%ピリジン含有)で精製した。この反応を2回行い目的化合物(14)(0.85 g)を得た。以下に、化合物(14)の機器分析値を示す。
化合物(14):
1H-NMR(500 MHz, CDCl3) δ: 7.43-7.41(2H, m), 7.32-7.26(6H, m), 7.21-7.18(1H, m), 6.87-6.85(1H, m), 6.83-6.80(4H, m), 6.51(1H, d,J=7.3 Hz), 4.43-4.38(1H, m), 3.79(6H, s), 3.67(3H, s), 3.63(2H, d, J=6.1 Hz), 3.28-3.25(2H, m), 3.02(2H, t, J=6.6 Hz), 2.54-2.48(1H, m), 2.38-2.32(1H, m), 2.20-2.17(2H, m), 2.14-2.07(1H, m), 1.96-1.89(1H, m), 1.64-1.53(8H, m), 1.40-1.34(2H, m)
化合物(14)(0.85 g, 1.3 mmol)をピリジンで共沸し、真空乾燥させた。つぎに、アセトニトリル(2.5 mL)とジイソプロピルアンモニウムテトラゾリド(0.27 g, 1.6 mmol)を加え、さらに2-シアノエチル-N,N,N’,N’-テトライソプロピルホスホロジアミダイト(0.47 g, 1.6 mmol)を加え、室温にて2時間撹拌した。反応終了後、減圧下溶媒留去し、酢酸エチルを加えて飽和炭酸水素ナトリウム水溶液で2回、飽和塩化ナトリウム水溶液で1回ずつ洗浄した。洗浄した有機層を無水硫酸ナトリウムにて乾燥後、減圧濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:2、0.1%トリエチルアミン含有)で精製し、目的化合物(15)(0.95 g, 純度92.%, 収率86.4%)を得た。以下に、化合物(15)の機器分析値を示す。
化合物(15):
1H-NMR(500 MHz, CDCl3) δ: 7.43-7.41(2H, m), 7.32-7.26(6H, m), 7.21-7.17(1H, m), 6.83-6.80(4H, m), 6.63-6.60(1H, m), 6.47(1H, d,J=7.4 Hz), 4.44-4.40(1H, m), 3.88-3.82(1H, m), 3.80-3.75(1H, m), 3.78(6H, s), 3.71-3.67(1H, m), 3.66(3H, s), 3.64-3.55(3H, m), 3.31-3.21(2H, m), 3.03(2H, t, J=6.4 Hz), 2.64(2H, t, J=6.4 Hz), 2.53-2.47(1H, m), 2.38-2.32(1H, m), 2.18(2H, t, J=7.5 Hz), 2.14-2.07(1H, m), 1.96-1.89(1H, m), 1.64-1.56(8H, m), 1.41-1.34(2H, m), 1.19-1.16(12H, m).
31P-NMR (202 MHz, CDCl3) δ: 147.89
ESI-Mass:867.49 [M+H2O+H]+
下記スキームに従い、化合物(5a-c)を合成した。
Fmoc-L-プロリン(3.0 g、8.9 mmol)を脱水N,N-ジメチルホルムアミド(50 mL)に溶かした。6-アミノ-1-ヘキサノール(1.3 g、1.2eq)および1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(2.0 g、1.2eq)、1-ヒドロキシベンゾトリアゾール(3.3g、2.4eq)を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後、反応混合物を減圧下にて溶媒を留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。得られた残渣をシリカゲルカラムクロマトグラフ(展開溶媒:ジクロロメタン-メタノール(20:1))に付し、目的物質を2.9 g(収率 75 %)得た。
1H-NMR(CDCl3): δ7.76-7.83(m,2H)、7.50-7.63(m,2H)、7.38-7.43 (m,2H)、7.27-7.34(m,2H),4.54-4.35(m,2H),4.13-4.35(m,2H),3.54-3.63(m,2H)、3.35-3.54(m,2H)、3.17―3.28(m,2H)、1.82-2.07(m,3H)、1.21-1.59(m,9H)
脱水ピリジンを用いて、化合物1a (2.9 g, 6.6 mmol)を共沸乾燥した。残渣を脱水ピリジン(40 mL)に溶かした。0℃にて4,4-ジメトキシトリチルクロリド(DMTrCl) (2.7 g, 1.2 eq.) を加えて室温にて終夜撹拌した。TLCにて原料の消失を確認後、メタノールを加えて30分撹拌した。減圧下にて溶媒留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。減圧乾燥し、油状物質を5.0 g得た。
化合物2a (5.0g, 6.6 mmol)を脱水N,N-ジメチルホルムアミド(40 mL)に溶かした。ピぺリジン(6.5 mL)を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後、反応混合物を減圧下にて溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフ(展開溶媒:ジクロロメタン-メタノール(20:1)、0.05% ピリジン)に付し、目的物質を2.6 g(収率 76 %、2段階)得た。
1H-NMR(CDCl3):δ7.44-7.49(m,2H)、7.28-7.38(m, 6H)、7.20-7.26(m, 1H)、6.83-6.88(m,4H)、3.83(s,6H)、3.70(dd,1H,J=9.2Hz,5.2Hz)、3.20(q, 2H,J=6.9Hz)、3.03(t,2H, J=6.6Hz)、2.97-3.00(m,1H)、2.86-2.93(m,1H)、2.10-2.21(m,1H)、1.58-1.97(m,5H)、1.25-1.57(m,6H)
化合物3a (2.5 g、4.8 mmol)をN,N-ジメチルホルムアミド (15 mL)に溶かした。8-ヒドロキシオクタン酸 (0.93 g、1.2eq)および1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(1.1 g、1.2eq)、1-ヒドロキシベンゾトリアゾール(1.8 g、2.4eq) をN,N-ジメチルホルムアミド (15 mL)に溶かした。0℃で化合物3aのN,N-ジメチルホルムアミド溶液を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後、反応混合物を減圧下に溶媒を留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。得られた残渣をシリカゲルカラムクロマトグラフ(展開溶媒:ジクロロメタン-メタノール(40:1)、0.05% ピリジン)に付し、目的物質を2.1 g(収率 71 %)得た。
1H-NMR(CDCl3):δ7.42-7.46(m,2H)、7.26-7.36(m, 6H)、7.16-7.24(m, 1H)、6.81-6.86(m,4H)、3.79(s,6H)、3.58-3.66(m,2H)、3.49-3.56(m,1H)、3.37-3.44(m,1H)、3.10-3.27(m,1H)、3.01 (2H, t, J = 6.6 Hz)、2.29-2.35(m,2H)、1.42-1.71(m,10H)、1.21-1.41(m,12H)
共沸乾燥した化合物4a (2.0 g, 2.6 mmol) のアセトニトリル溶液 (8 mL) に、ジイソプロピルアンモニウムテトラゾリド(DIPAT) (0.64 g, 1.2 eq.)を加えた。2-シアノエトキシ-N,N,N’,N’-テトライソプロピルホスホロジアミダイト (1.1 g, 1.2 eq.) のアセトニトリル溶液 (2 mL)を加え、室温にて2時間撹拌した。ジクロロメタンを加えて飽和重曹水および飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。アミノシリカを用いたカラムクロマトグラフ(展開溶媒:n-ヘキサン-酢酸エチル(1:1)、0.1 %トリエチルアミン)に残渣を付し、目的物質を2.1 g(収率81%)得た。
31P-NMR (CDCl3) : δ=147.821
ESI-Mass m/z:877.55 [M+H2O+H]+, 960.66 [M+TEA+H]+
Fmoc-L-プロリン(3.0 g、8.9 mmol)を脱水N,N-ジメチルホルムアミド(60mL)に溶かした。8-アミノ-1-オクタノール(1.5 g、1.2eq)および1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(2.0 g、1.2eq)、1-ヒドロキシベンゾトリアゾール(3.3g、2.4eq)を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後、反応混合物を減圧下にて溶媒を留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。得られた残渣をシリカゲルカラムクロマトグラフ(展開溶媒:ジクロロメタン-メタノール(20:1))に付し、目的物質を3.0 g(収率 73 %)得た。
1H-NMR(CDCl3): δ7.76-7.83(m,2H)、7.50-7.64(m,2H)、7.39-7.45(m,2H)、7.30-7.36(m,2H),4.58-4.37(m,2H),4.16-4.37(m,2H),3.57-3.65(m,2H)、3.38-3.57(m,2H)、3.10-3.30(m,2H)、1.82-2.07(m,3H)、1.21-1.59(m,13H)
脱水ピリジンを用いて、化合物1b (3.0 g, 6.5 mmol)を共沸乾燥した。残渣を脱水ピリジン(40 mL)に溶かした。0℃にて4,4-ジメトキシトリチルクロリド(DMTrCl) (2.6 g, 1.2 eq.) を加えて室温にて終夜撹拌した。TLCにて原料の消失を確認後、メタノールを加えて30分撹拌した。減圧下にて溶媒留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。減圧乾燥し、油状物質を5.0 g得た。
化合物2b (5.0g, 6.5mmol)を脱水N,N-ジメチルホルムアミド(40 mL)に溶かした。ピぺリジン(6.4 mL)を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後、反応混合物を減圧下にて溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフ(展開溶媒:ジクロロメタン-メタノール(15:1)、0.05% ピリジン)に付し、目的物質を2.9 g(収率 83 %、2段階)得た。
1H-NMR(CDCl3):δ7.43-7.47(m,2H)、7.26-7.37(m, 6H)、7.18-7.23(m, 1H)、6.81-6.86(m,4H)、3.80(s,6H)、3.71(dd,1H,J=9.2Hz,5.2Hz)、3.21(q, 2H,J=6.9Hz)、2.97-3.06(m,3H)、2.85-2.91(m,1H)、2.09-2.18(m,1H)、1.87-1.96(m,1H)、1.66-1.74(m,2H)、1.57-1.65(m,2H)、1.44-1.52(m,2H)、1.22-1.38(m,8H)
化合物3b (2.8 g、5.1 mmol)を脱水ジクロロメタン(40 mL)に溶かした。10-ヒドロキシデカン酸(1.2 g、1.2eq)および1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(1.2 g、1.2eq)、1-ヒドロキシベンゾトリアゾール(1.9g、2.4eq)、トリエチルアミン (2.6 mL) を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後、反応混合物を減圧下にて溶媒を留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。得られた残渣をシリカゲルカラムクロマトグラフ(展開溶媒:ジクロロメタン-メタノール(20:1)、0.05% ピリジン)に付し、目的物質を2.5 g(収率 70 %)得た。
1H-NMR(CDCl3):δ7.41-7.45(m,2H)、7.25-7.35(m, 6H)、7.16-7.21(m, 1H)、6.79-6.85(m,4H)、3.79(s,6H)、3.58-3.65(m,2H)、3.48-3.54(m,1H)、3.36-3.43(m,1H)、3.11-3.22(m,1H)、3.01 (2H, t, J = 6.6 Hz)、2.26-2.32(m,2H)、1.50-1.68(m,8H)、1.39-1.49(m,2H)1.19-1.38(m,20H)
共沸乾燥した化合物4b (2.4 g, 3.4 mmol) のアセトニトリル溶液 (8 mL) に、ジイソプロピルアンモニウムテトラゾリド(DIPAT) (0.69 g, 1.2 eq.)を加えた。2-シアノエトキシ-N,N,N’,N’-テトライソプロピルホスホロジアミダイト (1.2 g, 1.2 eq.) のアセトニトリル溶液 (2 mL)を加え、室温にて2時間撹拌した。ジクロロメタンを加えて飽和重曹水および飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。アミノシリカを用いたカラムクロマトグラフ(展開溶媒:n-ヘキサン-酢酸エチル(1:1)、0.1 %トリエチルアミン)に残渣を付し、目的物質を2.4 g(収率80%)得た。
31P-NMR (CDCl3) : δ=147.810
ESI-Mass m/z:937.56 [M+Na]+, 1016.70 [M+TEA+H]+
Fmoc-L-プロリン(3.0 g、8.9 mmol)を脱水アセトニトリル (75 mL)と脱水N,N-ジメチルホルムアミド(15 mL)の混合溶媒に溶かした。10-アミノ-1-デカノール (1.8 g、1.2eq)およびN,N'-ジシクロヘキシルカルボジイミド (2.2 g、1.2eq)、1-ヒドロキシベンゾトリアゾール(3.3g、2.4eq)を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後沈殿物をろ別し、ろ液を減圧下にて溶媒を留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。ジイソプロピルエーテルを用いてトリチレーションを行った。減圧乾燥し、固体物質を4.0 g(収率 93 %)得た。
1H-NMR(CDCl3): δ7.72-7.78(m,2H)、7.50-7.62(m,2H)、7.35-7.42(m,2H)、7.26-7.33(m,2H),4.54-4.33(m,2H),4.12-4.33(m,2H),3.57-3.62(m,2H)、3.34-3.54(m,2H)、3.06-3.26(m,2H)、1.80-2.04(m,3H)、1.13-1.47(m,17H)
脱水ピリジンを用いて、化合物1c (3.9 g, 8.0 mmol)を共沸乾燥した。残渣を脱水ピリジン(50 mL)に溶かした。0℃にて4,4-ジメトキシトリチルクロリド(DMTrCl) (3.2 g, 1.2 eq.) を加えて室温にて終夜撹拌した。TLCにて原料の消失を確認後、メタノールを加えて30分撹拌した。減圧下にて溶媒留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。減圧乾燥し、油状物質を6.2 g得た。
化合物2c (6.2g, 7.8 mmol)を脱水N,N-ジメチルホルムアミド(50 mL)に溶かした。ピぺリジン(7.7 mL)を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後、反応混合物を減圧下にて溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフ(展開溶媒:ジクロロメタン-メタノール(15:1)、0.05% ピリジン)に付し、目的物質を3.4 g(収率 76 %、2段階)得た。
1H-NMR(CDCl3):δ7.38-7.42(m,2H)、7.21-7.31(m, 6H)、7.13-7.18(m, 1H)、6.75-6.80(m,4H)、3.79(s,6H)、3.72(dd,1H,J=9.2Hz,5.7Hz)、3.21(q, 2H,J=6.9Hz)、2.98-3.03(m,3H)、2.80-2.88(m,1H)、2.05-2.15(m,1H)、1.83-1.91(m,1H)、1.66-1.74(m,2H)、1.52-1.59(m,2H)、1.38-1.48(m,2H)、1.16-1.34(m,12H)
化合物3c (2.4 g、4.2 mmol)をN,N-ジメチルホルムアミド (20 mL)に溶かした。12-ヒドロキシドデカン酸 (1.1 g、1.2eq)および1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(0.96 g、1.2eq)、1-ヒドロキシベンゾトリアゾール(1.5g、2.4eq) をN,N-ジメチルホルムアミド (20 mL)に溶かした。0℃で化合物3cのN,N-ジメチルホルムアミド溶液を加え、アルゴン雰囲気下、室温にて終夜撹拌した。反応終了後、反応混合物を減圧下に溶媒を留去した。得られた残渣にジクロロメタンを加え、飽和重曹水、飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。得られた残渣をシリカゲルカラムクロマトグラフ(展開溶媒:n-ヘキサン-酢酸エチル(1:3)、0.05% ピリジン)に付し、目的物質を2.1 g(収率 66 %)得た。
1H-NMR(CDCl3):δ7.41-7.45(m,2H)、7.25-7.34(m, 6H)、7.17-7.22(m, 1H)、6.79-6.83(m,4H)、3.79(s,6H)、3.58-3.67(m,2H)、3.47-3.56(m,1H)、3.35-3.44(m,1H)、3.09-3.29(m,1H)、3.02 (2H, t, J = 6.6 Hz)、2.25-2.35(m,2H)、1.53-1.65(m,9H)、1.18-1.39(m,29H)
共沸乾燥した化合物4c (2.0 g, 2.6 mmol) のアセトニトリル溶液 (8 mL) に、ジイソプロピルアンモニウムテトラゾリド(DIPAT) (0.53 g, 1.2 eq.)を加えた。2-シアノエトキシ-N,N,N’,N’-テトライソプロピルホスホロジアミダイト (0.94 g, 1.2 eq.) のアセトニトリル溶液 (2 mL)を加え、室温にて2時間撹拌した。ジクロロメタンを加えて飽和重曹水および飽和食塩水で洗浄した。有機相を硫酸ナトリウム乾燥後、溶媒留去した。アミノシリカを用いたカラムクロマトグラフ(展開溶媒:n-ヘキサン-酢酸エチル(1:1)、0.1 %トリエチルアミン)に残渣を付し、目的物質を1.9 g(収率76%)得た。
31P-NMR (CDCl3) : δ=147.821
ESI-Mass m/z:989.67 [M+H2O+H]+, 1072.78 [M+TEA+H]+
実施例2~5で合成した化合物5、10、15、5a、5b及び5cと、自体公知のプロリンジアミドアミダイト、リジンジアミドアミダイト、グリシンジアミドアミダイト、テレフタル酸ジアミドアミダイト、及びグリシルグリシンジアミドアミダイトを用いて、実施例1と同様の方法で、表2-1~表4に示すsgRNAを合成した。下記配列中、下線部は標的ヌクレオチド配列に相補的なガイド領域であり、、アミノ酸誘導体リンカーは表5に記載の通り、略称で示している。
ヒトKRAS遺伝子(GenBank accession No. NM_004985.3)のG12V変異を有する配列(NCBI Refference Sequence NP_0049762)を組み込んだプラスミドDNA(pCMV6-Entry-KRAS(G12V),OriGene Technologies)を、制限酵素Tth111I(TaKaRa)と添付のプロトコールに従い反応させた。反応終了後定法に従い精製し,終濃度100 ng/μLとなるようにTEバッファー(10 mM Tris-HCl, pH8,1 mM EDTA)に溶解し基質DNAとした。
上記基質DNAを、Cas9 Nuclease, S. pyogenes (New England Biolabs)に添付の試薬を用いてsgRNAおよびCas9と以下のように混合した;
100 ng 基質DNA + 0.5 ng sgRNA + 0.3 pmol Cas9(全量10μL)
37℃で15分間インキュベーションした後、さらに70℃で10分間インキュベーションしCas9を失活させた。その後電気泳動を行い、エチジウムブロマイド染色後ゲルイメージングシステムPXi4(SYNGENE社)を用いバンド強度を測定した。
測定結果を基に、下記の等式により切断効率を算出した。
Cleavage Efficiency=sum of cleaved band intensities/(sum of the cleaved and uncleaved band intensities)
その結果を図3~6に示す。ゲル下の数値は上記計算式により求めた切断効率を表している。さらに、参考例である天然型sgRNA(SG-0001)の切断効率を1としたときの本実施例の人工sgRNAの相対切断効率を図7に示した。
本実施例の人工sgRNAの多くは、参考例である天然型sgRNAと同等以上の切断効率を示し、各部位のアミノ酸誘導体による置換が有効であることがわかった。
ヒトBCL-2遺伝子(GenBank accession No. NM_000633)を組み込んだプラスミドDNA(pCAGGSHB2)を、制限酵素HindIII(TaKaRa)と添付のプロトコールに従い反応させた。反応終了後定法に従い精製し、終濃度100 ng/μLとなるようにTEバッファー(10 mM Tris-HCl, pH8,1 mM EDTA)に溶解し基質DNAとした。
上記基質DNAを、Cas9 Nuclease, S. pyogenes (NewEnglandBiolabs)に添付の試薬を用いてsgRNAおよびCas9と以下のように混合した;
100 ng 基質DNA + 10 ng sgRNA + 0.3 pmol Cas9 (全量10μL)
37℃で30分間インキュベーションした後、さらに70℃で10分間インキュベーションしCas9を失活させた。その後電気泳動を行い、エチジウムブロマイド染色後ゲルイメージングシステムPXi4(SYNGENE社)を用いバンド強度を測定した。
測定結果を基に、下記の等式により切断効率を算出した。
Cleavage Efficiency=sum of cleaved band intensities/(sum of the cleaved and uncleaved band intensities)
その結果を図8に示す。ゲル下の数値は上記計算式により求めた切断効率を表している。さらに、参考例である天然型sgRNA(SG-0017)の切断効率を1としたときの本実施例の人工sgRNAの相対切断効率を図9に示した。
本実施例の人工sgRNAは、参考例である天然型sgRNAと同等以上の切断効率を示し、各部位のアミノ酸誘導体による置換が有効であることがわかった。
ヒトBRAF遺伝子(GenBank accession No. NM_004333)のV600E変異を有する配列を組み込んだプラスミドDNA(pCMV6-Entry-BRAF(V600E),OriGene Technologies)を、制限酵素Tth111I(TaKaRa)と添付のプロトコールに従い反応させた。反応終了後定法に従い精製し、終濃度100 ng/μLとなるようにTEバッファー(10 mM Tris-HCl, pH8,1 mM EDTA)に溶解し基質DNAとした。
上記基質DNAを、Cas9 Nuclease, S. pyogenes (New England Biolabs)に添付の試薬を用いてsgRNAおよびCas9と以下のように混合した;
100 ng 基質DNA + 0.5ng sgRNA + 0.3 pmol Cas9(全量10μL)
37℃で15分間インキュベーションした後、さらに70℃で10分間インキュベーションしCas9を失活させた。その後電気泳動を行い、エチジウムブロマイド染色後ゲルイメージングシステムPXi4(SYNGENE社)を用いバンド強度を測定した。
測定結果を基に、下記の等式により切断効率を算出した。
Cleavage Efficiency=sum of cleaved band intensities/(sum of the cleaved and uncleaved band intensities)
その結果を図10に示す。ゲル下の数値は上記計算式により求めた切断効率を表している。さらに、参考例である天然型sgRNA(SG-0090)の切断効率を1としたときの本実施例の人工sgRNAの相対切断効率を図11に示した。
本実施例の人工sgRNAは、参考例である天然型sgRNAと同等以上の切断効率を示し、各部位のアミノ酸誘導体による置換が有効であることがわかった。
Jurkat細胞 (2×105個)をマイクロチューブに採取しPBSで洗浄した後、6 μg GeneArt Platinum Cas9 Nuclease (Thermo Fisher Scientific社)と1.2 μg sgRNAをNeon 10 μL tip(Thermo Fisher Scientific社)付属のReSuspension buffer Rに加えた被験物質溶液10 μLを用いて細胞を懸濁した。細胞懸濁液をNeon 10 μL tipに吸引し、Pulse Voltage 1700V, Pulse Width 20 ms, Pulse Number 1回の条件下でエレクトロポレーターNeon (Thermo Fisher Scientific社)を用いてトランスフェクションを行った。得られた細胞を10% Fetal Bovine Serum (MP Biomedicals)を含むRPMI1640 Medium (Thermo Fisher Scientific社) 500 μLを用いて24-well Dish(Thermo Fisher Scientific社)に播種した。37℃、5%CO2下で48時間培養後細胞を回収しPBSで洗浄した後、GeneArt(登録商標) Genomic Cleavage Detection Kit (Thermo Fisher Scientific社)を用いてゲノムDNAを精製した。得られたゲノムDNAの一部を鋳型として、ヒトBCL-2遺伝子増幅用プライマーセット:5’-ATCAAGTGTTCCGCGTGATTGAAGA-3’ / 5’- CTCACATCACCAAGTGCACCTACCC-3’を用いて、GeneArt(登録商標) Genomic Cleavage Detection Kit添付のプロトコールに従いPCRを行った。得られたPCR産物を用い、GeneArt(登録商標) Genomic Cleavage Detection Kitに添付のプロトコールに従い染色体in-del検出反応を行った後アガロースゲル電気泳動を行い、エチジウムブロマイド染色したゲルについてゲルイメージングシステムPXi4(SYNGENE社)を用いバンド強度を測定した。
測定結果を基に、下記の等式により切断効率を算出した。
Cleavage Efficiency= 1- [(1-fraction cleaved) 1/2]
Fraction Cleaved= sum of cleaved band intensities/(sum of the cleaved and parental band intensities)
その結果を図12に示す。ゲル下の数値は上記計算式により求めた切断効率を表している。さらに、参考例である天然型sgRNA(SG-0017)の切断効率を1としたときの本実施例の人工sgRNAの相対切断効率を図13に示した。
本実施例の人工sgRNAの中には、細胞内においても、参考例である天然型sgRNAと同等以上の切断効率を示すものがあった。
A-375細胞 (5.6×104個)をマイクロチューブに採取しPBSで洗浄した後、6 μg GeneArt Platinum Cas9 Nuclease (Thermo Fisher Scientific社)と1.2 μg sgRNAをNeon 10 μL tip(Thermo Fisher Scientific社)付属のReSuspension buffer Rに加えた被験物質溶液10 μLで細胞を懸濁した。細胞懸濁液をNeon 10 μL tipに吸引し、Pulse Voltage 1400V, Pulse Width 20 ms, Pulse Number 2回の条件下でエレクトロポレーターNeon (Thermo Fisher Scientific社)を用いてトランスフェクションを行った。得られた細胞を10% Fetal Bovine Serum (MP Biomedicals)を含むDulbecco’s Modified Eagle’s Medium (High Glucose) (Sigma Aldrich社) 500 μLを用いて24-well Dish(Thermo Fisher Scientific社)に播種した。37℃、5%CO2下で48時間培養後細胞をPBSで洗浄した後、GeneArt(登録商標) Genomic Cleavage Detection Kit (Thermo Fisher Scientific社)を用いてゲノムDNAを精製した。得られたゲノムDNAの一部を鋳型として、ヒトBRAF遺伝子増幅用プライマーセット:5’-CGCCCAGGAGTGCCAAGAGAATATC-3’ / 5’- CAGCAGCATCTCAGGGCCAAAAAT-3’を用いて、GeneArt(登録商標) Genomic Cleavage Detection Kit添付のプロトコールに従いPCRを行った。得られたPCR産物を用い、GeneArt(登録商標) Genomic Cleavage Detection Kitに添付のプロトコールに従い染色体in-del検出反応を行った後アガロースゲル電気泳動を行い、エチジウムブロマイド染色したゲルについてゲルイメージングシステムPXi4(SYNGENE社)を用いバンド強度を測定した。
測定結果を基に、下記の等式により切断効率を算出した。
Cleavage Efficiency= 1- [(1-fraction cleaved) 1/2]
Fraction Cleaved= sum of cleaved band intensities/(sum of the cleaved and parental band intensities)
その結果を図14に示す。ゲル下の数値は上記計算式により求めた切断効率を表している。さらに、参考例である天然型sgRNA(SG-0090)の切断効率を1としたときの本実施例の人工sgRNAの相対切断効率を図15に示した。
本実施例の人工sgRNAの中には、細胞内においても、参考例である天然型sgRNAと同等以上の切断効率を示すものがあった。
ここで述べられた特許および特許出願明細書を含む全ての刊行物に記載された内容は、ここに引用されたことによって、その全てが明示されたと同程度に本明細書に組み込まれるものである。
本出願は、2016年1月30日付で日本国に出願された特願2016-016743を基礎としており、ここで言及することによりその内容は全て本明細書に包含される。
Claims (44)
- 下式(A):
[式(A)中、Xaは、下式(I):
(式(I)中、
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
L1は、n個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
mは、0~30の整数であり;
nは、0~30の整数であり;
R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(I)であり、
Aは、任意の原子団であり、ただし、下式(Ia)は、アミノ酸またはペプチドである。)で表わされるアミノ酸誘導体リンカーであり、
前記Xaは、前記-OR1-または-OR2-を介して隣接するヌクレオチド残基に結合し、
式(A)中、Xb及びYは、それぞれ独立して、1ないし5個の任意のヌクレオチドリンカーであるか、あるいは、上記式(I)で表わされるアミノ酸誘導体リンカーであり、
前記Xb及びYは、それぞれ独立して、前記-OR1-または-OR2-を介して隣接するヌクレオチド残基に結合し、
式(A)中、Xc及びXdは、存在しても存在しなくてもよく、存在する場合、それぞれ独立して、前記式(I)で表わされるアミノ酸誘導体リンカーであり、
前記Xc及びXdは、それぞれ独立して、前記-OR1-または-OR2-を介して隣接するヌクレオチド残基に結合し、
式(A)中、(n)20は、それぞれ独立してA、G、CまたはUである20±5個のヌクレオチド残基からなるヌクレオチド配列である。]で表わされる、単一ガイドRNA、あるいは
(2)前記式(A)において、(n)20を除く領域で1ないし数個のヌクレオチド残基が置換、欠失、挿入もしくは付加され、かつCas9タンパク質と複合体を形成して前記(n)20に相補的な標的ヌクレオチド配列を含む二本鎖DNAを認識する活性を有する、単一ガイドRNA。 - 前記式(Ia)のアミノ酸またはペプチドを構成するアミノ酸が、置換基または保護基を有していてもよい、グリシン、α-アラニン、アルギニン、アスパラギン、アスパラギン酸、システイン、シスチン、グルタミン、グルタミン酸、ヒスチジン、イソロイシン、ロイシン、リシン、ヒドロキシリシン、メチオニン、フェニルアラニン、セリン、トレオニン、チロシン、バリン、プロリン、4-ヒドロキシプロリン、トリプトファン、β-アラニン、1-アミノ-2-カルボキシシクロペンタン、アミノ安息香酸、アミノピリジンカルボン酸、および下記化学式(Ia2):
(式(Ia2)中、R100は、任意の置換基であり、存在しても存在しなくてもよく、存在する場合は、1個でも複数でもよく、複数の場合は、互いに同一でも異なっていてもよい。)で表されるアミノ酸からなる群より選択される少なくとも1種である、請求項1記載の単一ガイドRNA。 - 前記Xaが、前記式(I-4)または(I-7)で表され、該式中、n=5およびm=4である、請求項3記載の単一ガイドRNA。
- 前記Xaが、前記式(I-1)で表され、該式中、n=5およびm=4である、または前記式(I-6)で表され、該式中、n=4およびm=4である、[3]記載の単一ガイドRNA。
- 前記Xaが、下式(II):
(式(II)中、
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
R3は、環A上のC-3、C-4、C-5またはC-6に結合する水素原子または置換基であり;
L1は、n個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
lは、1または2であり;
mは、0~30の整数であり;
nは、0~30の整数であり;
環Aは、前記環A上のC-2以外の1個の炭素原子が、窒素、酸素または硫黄で置換されてもよく、
前記環A内に、炭素-炭素二重結合または炭素-窒素二重結合を含んでもよく、
R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(II)であり、
前記Xaは、-OR1-または-OR2-を介して、隣接するヌクレオチド残基に結合する。)で表される、請求項1または2記載の単一ガイドRNA。 - 前記Xaが、前記式(II-8)で表され、該式中、n=5およびm=4、n=7およびm=6、n=9およびm=8、またはn=11およびm=10である、請求項7記載の単一ガイドRNA。
- 前記各式中、n=5およびm=4である、請求項9記載の単一ガイドRNA。
- 前記Xb及びYが、それぞれ独立して、1ないし5個の任意のヌクレオチドリンカーである、請求項1~10のいずれか一項に記載の単一ガイドRNA。
- 前記Xc及びXdが存在しない、請求項11記載の単一ガイドRNA。
- 前記Xc及びXdが、それぞれ独立して、前記式(I)で表わされるアミノ酸誘導体リンカーである、請求項11記載の単一ガイドRNA。
- 前記Xc及びXdが、前記式(II)で表わされるアミノ酸誘導体リンカーである、請求項13記載の単一ガイドRNA。
- 前記Xc及びXdが、前記式(II-8)で表わされ、該式中、n=5およびm=4である、請求項14記載の単一ガイドRNA。
- 前記Xc及びXdが、前記式(I-1)、(I-4)、(I-7)及び(III-1)~(III-3)のいずれかで表わされ、該式中、n=5およびm=4であるか、あるいは、前記式(I-6)で表わされ、該式中、n=4およびm=4である、請求項13記載の単一ガイドRNA。
- 前記Xbが、前記式(I)で表されるアミノ酸誘導体リンカーである、請求項1~10のいずれか一項に記載の単一ガイドRNA。
- 前記Xbが、前記式(II)で表わされるアミノ酸誘導体リンカーである、請求項17記載の単一ガイドRNA。
- 前記Xbが、前記式(II-8)で表わされ、該式中、n=5およびm=4である、請求項18記載の単一ガイドRNA。
- 前記Xbが、前記式(I-1)、(I-4)、(I-7)及び(III-1)~(III-3)のいずれかで表わされ、該式中、n=5およびm=4であるか、あるいは、前記式(I-6)で表わされ、該式中、n=4およびm=4である、請求項17記載の単一ガイドRNA。
- 前記Yが、1ないし5個の任意のヌクレオチドリンカーである、請求項17~20のいずれか一項に記載の単一ガイドRNA。
- 前記Yが、前記式(I)で表されるアミノ酸誘導体リンカーである、請求項17~20のいずれか一項に記載の単一ガイドRNA。
- 前記Yが、前記式(I-4)で表され、該式中、n=5およびm=4である、請求項22記載の単一ガイドRNA。
- 前記Yが、前記式(II)で表されるアミノ酸誘導体リンカーである、請求項22記載の単一ガイドRNA。
- 前記Yが、前記式(II-8)で表され、該式中、n=5およびm=4、n=7およびm=6、n=9およびm=8、またはn=11およびm=10である、請求項24記載の単一ガイドRNA。
- 前記Yが、前記式(I-1)、(I-7)及び(III-1)~(III-3)のいずれかで表わされ、該式中、n=5およびm=4であるか、あるいは、前記式(I-6)で表わされ、該式中、n=4およびm=4である、請求項22記載の単一ガイドRNA。
- 前記Xaが、前記式(II-8)で表され、該式中、n=5およびm=4であり、かつ前記Xaに隣接するステムの1~3塩基対が欠失した、請求項7記載の単一ガイドRNA。
- 前記Xbに隣接するステムの1~4塩基対が欠失した、請求項19記載の単一ガイドRNA。
- 前記Xaが、前記式(II-8)で表され、該式中、n=5およびm=4であり、かつ前記Xaに隣接するステムの1~3塩基対が欠失した、請求項28記載の単一ガイドRNA。
- 前記式(A)で表される単一ガイドRNAであって、該式中、Xa、Xb及びYは1ないし5個の任意のヌクレオチドリンカーであり、Xc及びXdは存在せず、ステム-ループ1のループ部分(UA)もしくはステム-ループ3のループ部分(AGU)が、前記式(II-8)で表され、該式中、n=5およびm=4であるアミノ酸誘導体リンカーで置換されている、単一ガイドRNA。
- 請求項1~30のいずれか一項に記載の単一ガイドRNAと、Cas9とを組み合わせてなる、CRISPR/Cas9システム。
- Cas9がStreptococcus pyogenes由来である、請求項31記載のCRISPR/Cas9システム。
- Cas9が、タンパク質、それをコードするmRNAまたはそれをコードするDNAを含む発現ベクターの形態である、請求項31または32記載のCRISPR/Cas9システム。
- 請求項31~33のいずれか一項に記載のCRISPR/Cas9システムを、標的二本鎖DNAに接触させることを含む、該二本鎖DNAの認識方法。
- Cas9タンパク質が二本鎖DNA切断活性を有する、請求項34記載の方法。
- 前記二本鎖DNAの切断が細胞内で行われる、請求項35記載の方法。
- 標的遺伝子をノックアウトするための、請求項36記載の方法。
- 標的遺伝子内の塩基を改変するか、あるいは該遺伝子内に外因性遺伝子を挿入するための、請求項36記載の方法。
- 前記各式中、n=5およびm=4である、請求項39記載のモノマー。
- 核酸分子の製造方法であって、請求項39または40記載のモノマーを使用することを特徴とする、方法。
- 前記核酸分子が、請求項1~26のいずれか一項に記載の単一ガイドRNAである、請求項41記載の方法。
- 核酸分子の製造のための、請求項39または40記載のモノマーの使用。
- 前記核酸分子が、請求項1~26のいずれか一項に記載の単一ガイドRNAである、請求項43記載の使用。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17744466.8A EP3409776A4 (en) | 2016-01-30 | 2017-01-30 | ARN UNIQUE ARTIFICIAL GUIDE AND ITS USE |
CN201780021860.5A CN109072224B (zh) | 2016-01-30 | 2017-01-30 | 人工单导rna及其用途 |
US16/073,998 US11518994B2 (en) | 2016-01-30 | 2017-01-30 | Artificial single guide RNA and use thereof |
CA3013179A CA3013179A1 (en) | 2016-01-30 | 2017-01-30 | Artificial single guide rna and use thereof |
AU2017213405A AU2017213405B2 (en) | 2016-01-30 | 2017-01-30 | Artificial single guide RNA and use thereof |
KR1020187024080A KR102255995B1 (ko) | 2016-01-30 | 2017-01-30 | 인공 단일 가이드 rna 및 이의 용도 |
JP2017563895A JP6800171B2 (ja) | 2016-01-30 | 2017-01-30 | 人工単一ガイドrna及びその用途 |
AU2021202749A AU2021202749A1 (en) | 2016-01-30 | 2021-05-03 | Artificial single guide RNA and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-016743 | 2016-01-30 | ||
JP2016016743 | 2016-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017131237A1 true WO2017131237A1 (ja) | 2017-08-03 |
Family
ID=59398320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/003251 WO2017131237A1 (ja) | 2016-01-30 | 2017-01-30 | 人工単一ガイドrna及びその用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11518994B2 (ja) |
EP (1) | EP3409776A4 (ja) |
JP (2) | JP6800171B2 (ja) |
KR (1) | KR102255995B1 (ja) |
CN (1) | CN109072224B (ja) |
AU (2) | AU2017213405B2 (ja) |
CA (1) | CA3013179A1 (ja) |
WO (1) | WO2017131237A1 (ja) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
WO2019066378A1 (ko) * | 2017-09-28 | 2019-04-04 | 주식회사 녹십자 | Factor viii 또는 factor ix 유전자가 녹아웃된 토끼, 이의 제조방법 및 그 용도 |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
WO2021193954A1 (ja) * | 2020-03-27 | 2021-09-30 | 住友化学株式会社 | 核酸オリゴマーの製造方法 |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
JP2022523055A (ja) * | 2019-01-25 | 2022-04-21 | シンテゴ コーポレイション | Crispr活性をモジュレートするための系および方法 |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
JP7152094B1 (ja) | 2022-06-30 | 2022-10-12 | リージョナルフィッシュ株式会社 | tracrRNAユニット、及びゲノム編集方法 |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
EP3823633A4 (en) * | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC GUIDANCE MOLECULES, COMPOSITIONS AND METHODS RELATED |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3294880A4 (en) * | 2015-05-15 | 2018-12-26 | Dharmacon, Inc. | Synthetic single guide rna for cas9-mediated gene editing |
CA3048434A1 (en) * | 2016-12-30 | 2018-07-05 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
WO2022120027A1 (en) * | 2020-12-02 | 2022-06-09 | Arizona Board Of Regents On Behalf Of Arizona State University | Silica-based chromatographic processes for isolating nucleic acid-protein complexes and detecting target nucleic acids |
EP4284925A1 (en) * | 2021-01-26 | 2023-12-06 | California Institute of Technology | Allosteric conditional guide rnas for cell-selective regulation of crispr/cas |
CN113512767B (zh) * | 2021-04-30 | 2022-09-23 | 天津诺禾致源生物信息科技有限公司 | 用于构建small RNA文库的接头、试剂盒及small RNA文库的构建方法 |
WO2023081687A1 (en) * | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015006747A2 (en) * | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use. |
WO2015099187A1 (ja) * | 2013-12-27 | 2015-07-02 | 株式会社ボナック | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 |
CN105755040A (zh) * | 2016-01-21 | 2016-07-13 | 北京大学 | 一种改造的sgRNA及染色体标记应用 |
WO2016164356A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG196779A1 (en) | 2010-07-08 | 2014-02-13 | Bonac Corp | Single-strand nucleic acid molecule for controlling gene expression |
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
KR101849801B1 (ko) * | 2010-08-03 | 2018-04-17 | 가부시키가이샤 보낙 | 함질소 지환식 골격을 갖는 일본쇄 핵산 분자 |
US8691782B2 (en) | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
WO2013077446A1 (ja) | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
WO2013103146A1 (ja) | 2012-01-07 | 2013-07-11 | 株式会社ボナック | アミノ酸骨格を有する一本鎖核酸分子 |
WO2013133393A1 (ja) | 2012-03-07 | 2013-09-12 | 学校法人東京医科大学 | Vegf遺伝子の発現抑制用一本鎖核酸分子 |
MX362866B (es) * | 2012-05-25 | 2019-02-20 | Univ California | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn. |
JP6126088B2 (ja) | 2012-05-26 | 2017-05-10 | 株式会社ボナック | デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子 |
WO2014124226A1 (en) * | 2013-02-07 | 2014-08-14 | The Rockefeller University | Sequence specific antimicrobials |
JP2016519652A (ja) * | 2013-03-14 | 2016-07-07 | カリブー・バイオサイエンシーズ・インコーポレイテッド | 核酸ターゲティング核酸の組成物および方法 |
WO2015093495A1 (ja) * | 2013-12-16 | 2015-06-25 | 株式会社ボナック | TGF-β1遺伝子発現制御のための一本鎖核酸分子 |
JP6190995B2 (ja) * | 2014-11-17 | 2017-09-06 | 国立大学法人 東京医科歯科大学 | 簡便で高効率の遺伝子改変非ヒト哺乳動物の作製方法 |
US11268144B2 (en) * | 2015-09-24 | 2022-03-08 | Sigma-Aldrich Co. Llc | Methods and reagents for molecular proximity detection using RNA-guided nucleic acid binding proteins |
-
2017
- 2017-01-30 CA CA3013179A patent/CA3013179A1/en active Pending
- 2017-01-30 US US16/073,998 patent/US11518994B2/en active Active
- 2017-01-30 EP EP17744466.8A patent/EP3409776A4/en not_active Withdrawn
- 2017-01-30 KR KR1020187024080A patent/KR102255995B1/ko active IP Right Grant
- 2017-01-30 JP JP2017563895A patent/JP6800171B2/ja active Active
- 2017-01-30 AU AU2017213405A patent/AU2017213405B2/en not_active Ceased
- 2017-01-30 WO PCT/JP2017/003251 patent/WO2017131237A1/ja active Application Filing
- 2017-01-30 CN CN201780021860.5A patent/CN109072224B/zh not_active Expired - Fee Related
-
2020
- 2020-07-02 JP JP2020115250A patent/JP7096604B2/ja active Active
-
2021
- 2021-05-03 AU AU2021202749A patent/AU2021202749A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015006747A2 (en) * | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use. |
WO2015099187A1 (ja) * | 2013-12-27 | 2015-07-02 | 株式会社ボナック | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 |
WO2016164356A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
CN105755040A (zh) * | 2016-01-21 | 2016-07-13 | 北京大学 | 一种改造的sgRNA及染色体标记应用 |
Non-Patent Citations (2)
Title |
---|
DATABASE REGISTRY [o] 17 April 2017 (2017-04-17), "Benzenepropanamide , N-hydroxy-alpha-[(2- hydroxyacetyl)amino", retrieved from STN Database accession no. 1103513-06-9 * |
See also references of EP3409776A4 * |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12006520B2 (en) | 2011-07-22 | 2024-06-11 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11999947B2 (en) | 2016-08-03 | 2024-06-04 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2019066378A1 (ko) * | 2017-09-28 | 2019-04-04 | 주식회사 녹십자 | Factor viii 또는 factor ix 유전자가 녹아웃된 토끼, 이의 제조방법 및 그 용도 |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
EP3823633A4 (en) * | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC GUIDANCE MOLECULES, COMPOSITIONS AND METHODS RELATED |
JP2022523055A (ja) * | 2019-01-25 | 2022-04-21 | シンテゴ コーポレイション | Crispr活性をモジュレートするための系および方法 |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
WO2021193954A1 (ja) * | 2020-03-27 | 2021-09-30 | 住友化学株式会社 | 核酸オリゴマーの製造方法 |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
JP7152094B1 (ja) | 2022-06-30 | 2022-10-12 | リージョナルフィッシュ株式会社 | tracrRNAユニット、及びゲノム編集方法 |
JP2024006091A (ja) * | 2022-06-30 | 2024-01-17 | リージョナルフィッシュ株式会社 | tracrRNAユニット、及びゲノム編集方法 |
WO2024005186A1 (ja) * | 2022-06-30 | 2024-01-04 | リージョナルフィッシュ株式会社 | tracrRNAユニット、及びゲノム編集方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2020198880A (ja) | 2020-12-17 |
CA3013179A1 (en) | 2017-08-03 |
JP7096604B2 (ja) | 2022-07-06 |
KR20180100692A (ko) | 2018-09-11 |
CN109072224A (zh) | 2018-12-21 |
KR102255995B1 (ko) | 2021-05-25 |
EP3409776A4 (en) | 2019-12-25 |
AU2017213405A1 (en) | 2018-09-13 |
AU2017213405B2 (en) | 2021-02-04 |
US11518994B2 (en) | 2022-12-06 |
AU2021202749A1 (en) | 2021-05-27 |
US20190382758A1 (en) | 2019-12-19 |
JPWO2017131237A1 (ja) | 2018-11-01 |
CN109072224B (zh) | 2022-07-15 |
JP6800171B2 (ja) | 2020-12-16 |
EP3409776A1 (en) | 2018-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7096604B2 (ja) | 人工単一ガイドrna及びその用途 | |
JP5876890B2 (ja) | アミノ酸骨格を有する一本鎖核酸分子 | |
JP5261677B2 (ja) | 含窒素脂環式骨格を有する一本鎖核酸分子 | |
JP6162182B2 (ja) | 遺伝子発現制御のための一本鎖核酸分子 | |
WO2013077446A1 (ja) | 遺伝子発現制御のための一本鎖核酸分子 | |
JP2013153736A (ja) | ペプチド骨格を有する一本鎖核酸分子 | |
JP2013055913A (ja) | 遺伝子発現制御のための一本鎖rna分子 | |
WO2022045224A1 (ja) | 標的遺伝子の発現を抑制する新規な核酸分子 | |
JP2023127512A (ja) | 標的遺伝子の発現を抑制する核酸分子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17744466 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017563895 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3013179 Country of ref document: CA Ref document number: 260873 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187024080 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020187024080 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017744466 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017744466 Country of ref document: EP Effective date: 20180830 |
|
ENP | Entry into the national phase |
Ref document number: 2017213405 Country of ref document: AU Date of ref document: 20170130 Kind code of ref document: A |